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OVERVIEW OF CARDIAC AMINO ACID METABOLISM 
 
Published in Experimental Biology and Medicine1 
Exp Biol Med. 2012 Dec;237(12):1369-78.  
 
Introduction 
The heart is a highly active organ that consumes 10% of the body’s total 
oxygen uptake and produces upwards of 35 kg of ATP every day.2 This high rate 
of energy flux is required to accomplish the monumental task of pumping over 
6500 liters of blood per day at a relatively constant pressure and flow rate in the 
average human heart. This extraordinary amount of work requires a constant 
supply of metabolic substrates and oxygen. (Figure 1-1) 
An understanding of metabolism is essential for any study of the heart. 
Metabolism is the fundamental system that governs the entire organ’s behavior 
and it ties together all fields of study, including molecular physiology, 
electrophysiology, toxicology and clinical cardiology. All cardiac behaviors are 
highly ATP-dependent and, without ATP, the heart will cease to function in a 
matter of minutes. In many types of heart disease and dysfunction, metabolism is 
the first area affected, which can then lead to channelopathies, ion imbalance, 
decreased contractile function, increased free radical production and cardiac 
death. Amino acids play a central role in cardiac metabolism, but their 
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cardioprotective roles as a source of acetyl-CoA and as a substrate for 
anaplerotic reactions during cardiac ischemia, their ability to contribute to NADH 
and FADH2 production after reoxygenation, and the conversion of glutamine and 
glutamate to free radical scavengers may not be fully appreciated. 
Fortunately, the heart is also quite resilient, being able to maintain 
contractile function even under ischemic and anoxic conditions. It has been 
shown that an increase in non-oxidative ATP production in the ischemic and 
reperfused heart is associated with decreased cell death and increased 
functional recovery both in vivo and in culture, though the mechanism is not 
entirely clear.3-8 In this light, it is important to recognize the heart as a metabolic 
 
 
Figure 1-1. Metabolite supply and function in the heart. The heart is capable 




omnivore; it is capable of utilizing glucose, lactate, fatty acids, ketone bodies and 
certain amino acids as metabolic substrates.4, 9-13  
This ability is especially important under conditions of prolonged stress or 
ischemia. Deprived of fatty acid oxidation by the loss of their oxygen supply, 
cardiomyocytes must derive energy from other molecules including amino acids. 
It is well known that the heart’s primary metabolic substrates under normal 
conditions are fatty acids and lactate, but under conditions unfavorable for 
oxidation, i.e., ischemia, anoxia and many types of cardiomyopathy, fatty acid 
oxidation is inhibited and the heart preferentially performs glycolysis and 
substrate-level phosphorylation.14, 15  
Amino acids are now becoming more widely appreciated as cardioprotective 
substrates, as evidenced by the recent increase in excellent review articles 
detailing the importance of cardiac amino acid metabolism.16, 17 Glucose, fatty 
acids and other substrates require oxygen for full energy yield and produce 
significant levels of acidic by-products.14 Amino acids are of particular interest in 
this regard due to their potential for non-oxidative metabolism and their low 
contribution to cellular acidification. It may be possible to prolong cellular function 
during – and improve recovery after – anoxia by supplementing cells with 
glutamate and glutamine due to the ease with which these particular amino acids 
can be converted to α-ketoglutarate, a TCA cycle intermediate.18-21 Other amino 
acids, such as asparagine and aspartate, may also be important metabolic 
indicators due to their ability to remove amine groups and excess TCA cycle 
intermediates downstream from the conversion to succinate. The ability to 
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produce ATP directly from glutamine and glutamate through substrate-level 
phosphorylation makes these amino acids important for ischemic and 
hypertrophied hearts as they begin to suffer loss of function and increasing 
metabolic damage from free radicals and low pH. It should be noted, however, 
that glutamate and glutamine can provide only a small amount of ATP through 
this mechanism and that the reducing environment of the ischemic heart can 
inhibit these reactions. Each molecule of glutamate or glutamine can produce 
one GTP and one NADH molecule in their conversion to succinate. This is, 
however, an anaerobic process, does not contribute to acidification and may 
serve to maintain the levels of NADH and TCA cycle intermediates through an 
ischemic event, keeping the metabolic machinery primed to begin oxidative 
phosphorylation as soon as oxygen returns. 
Since amino acids are synthesized in a wide variety of pathways and 
reactions, some amino acids are more readily converted to metabolic 
intermediates than others. This is especially true in the heart, as the heart is 
completely unable to metabolize the aromatic amino acids, whereas alanine is 
synthesized and secreted in abundance under even the most favorable 
conditions. Other amino acids, like glutamate, glutamine, aspartate, asparagine 
and the branched chain amino acids (BCAAs), have been shown to be 
preferentially used as metabolic and anaplerotic substrates in the TCA cycle 
during anoxia and ischemia.22-24  
Although it is well known that the heart is capable of metabolizing a wide 
variety of substrates (Figure 1-2), the heart’s substrate preference under 
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anaerobic conditions is not well understood. Anoxic and ischemic tissues suffer 
from several issues of supply and demand: 1) inadequate substrate supply, 2) 
unmet energetic demands, 3) excess acid and reactive oxygen species (ROS) 
production and 4) inadequate buffering capacity for these metabolic by-products.  
Without oxygen, the heart cannot break down fatty acids and ketone bodies 
into acetyl-CoA. This becomes especially important during acute ischemia, as a 
lower pH also inhibits glycolysis, forcing the heart to utilize metabolic substrates 
that do not require oxidation and do not require glycolytic conversion, which 
 
Figure 1-2. Amino acids and the TCA cycle. The amino acid conversions are 
all reversible and hence are not drawn with arrows.  In the glutamate, alanine 
and aspartate transamination reactions, any amino acid can be used as an 




contributes to increased acidification. Certain amino acids could serve in this 
capacity.13  
It is important to note that while amino acid metabolism may have several 
important functions and provides a measure of protection against ischemia and 
anoxia, it is not capable of sustaining the heart’s extraordinary energy demands 
for extended periods. Amino acids should be viewed as an adjuvant for standard 
therapies in that they will extend the length of time between the onset of ischemia 
and the point of irreversible cardiac damage. In the case of cardiac ischemia, 
ROS production and metabolic demands will far outstrip the supply of 
antioxidants and metabolic substrates, but even minor increases in these stores 
should improve the function and recovery of the tissues over unsupplemented 
hearts. 
 
Amino Acid Metabolism in the Heart 
Amino acids seem to be especially well suited for use as metabolic 
substrates in the absence of adequate tissue perfusion. Glutamate and glutamine 
are notable due to their ready conversion to α-ketoglutarate, which not only 
maintains the levels of TCA cycle intermediates, but also provides cellular energy 
through substrate-level phosphorylation during the conversion to succinate. This 
is an oxygen-free metabolic conversion, with no acidic or reactive by-products. 
Indeed, changes in amino acid flux have been seen at rest as well as during 
ischemia, indicating that repeated bouts of acute ischemia induce biochemical 
changes that enhance the heart’s ability to utilize these alternative substrates.22 
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Peuhkurinen et al. specifically indicates that chronic ischemia results in increased 
glutamate uptake and alanine release.25 Nishimura et al. demonstrated the 
heart’s ability to utilize valine as an alternative to glucose in order to maintain 
action potential duration (APD).4 Studies conducted by Schwartz et al. indicated 
that BCAAs are metabolized by the myocardium even during normal cardiac 
function,23 though this has not been seen in all studies.22, 24 The heart is unable 
to produce the aromatic amino acids (phenylalanine, tyrosine and tryptophan) so 
uptake of other amino acids without commensurate uptake of aromatic amino 
acids indicates that the amino acids are not being used for protein synthesis.2, 9-
11, 26 Indeed, amino acids are still consumed even when there is no net protein 
synthesis or when protein is being degraded, indicating that the amino acids are 
being metabolized.25-27 Glutamine supplementation leads to rapid glutamine 
uptake and increased levels of intracellular glutamate due to high levels of 
glutaminase activity in the heart.18 Cardiac ischemia and cell damage therefore 
are expected to be accompanied by altered amino acid flux during and after 
ischemic episodes.  
 Amino acids can be readily metabolized into TCA cycle intermediates; 
however, not all amino acids are metabolized equally in the heart. There are 
several different processes by which amino acids can be used to supply 
cardiomyocytes with energy (Table 1-1): 
1. Glutamate and α-ketoglutarate are readily interconvertible via a 
transamination reaction. This increase in TCA cycle intermediates is 
called anaplerosis and contributes to the maintenance of oxidative 
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capacity. The α-ketoglutarate can then be processed through the TCA 
cycle to yield NADH and GTP. Glutamine can be converted to 
glutamate, or glutamate can be amidated in order to transport amine 
groups out of the cell. Glutamate, however, is also a neurotransmitter 
and may interfere with normal function of the nervous system, causing 
unintended side effects. Glutamine does not suffer from this shortfall 
and can be supplemented at very high levels relative to glutamate. 28 




2. Asparagine can serve as a means of exporting nitrogen from the cell, 
or it can be converted to aspartate. Aspartate can be transaminated to 
oxaloacetate, a crucial regulator of levels of TCA cycle intermediates. 
This reaction is critical, as it allows aspartate and asparagine stores to 
serve as sinks for excess oxaloacetate produced from supplemented 
α-ketoglutarate precursors.  
3. Alanine can also be transaminated to become pyruvate. Pyruvate 
oxidation produces three molecules of NADH and one of GTP. 
However, alanine is usually transported out of the myocardium to 
remove amine groups from the working cell. 
4. Many amino acids can be catabolized by the heart, through many 
different pathways, and the energy recovery from each will vary. 24, 25, 
29, 30 The BCAAs, for example, can be converted to acetyl-CoA, 
pyruvate or succinyl-CoA through somewhat lengthy conversion 
processes, or transaminated with 2-oxoglutarate to form their 
respective oxoacids and glutamate.25 This makes their involvement in 
metabolism difficult to quantify. A recent review by Huang et al. 
explored the important role of BCAAs in the failing heart.16 
In the fully functional heart, amino acid metabolism makes up a very small 
percentage of cardiac ATP production, but as the heart becomes oxygen-limited, 
amino acids become more important as a fuel source. 9, 10, 21, 30 Without oxygen, 
the fatty acids cannot be broken down into acetyl-CoA.14, 31 There is also a 
decrease in fatty acid consumption and an increase in glycolysis in hypertrophied 
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hearts, despite sufficient oxygen.13, 32, 33 Glucose and glycolysis become the 
primary means of producing ATP, but this yields far less energy per molecule 
and produces two protons per molecule of glucose consumed.10, 13, 34, 35 This 
energy deficit and acidification increase become especially important during 
acute ischemia, as a lower pH inhibits glycolysis.2, 13 The heart is eventually 
unable to produce sufficient ATP through glycolysis, and will out of necessity turn 
to anaerobic, non-glycolytic fuels, such as amino acids. It is unlikely that these 
fuels will be able to meet the cardiac metabolic demand for more than a brief 
interval, but any increase in function is associated with lower mortality. 
Amino acids are of particular interest as metabolites in the ischemic, 
diseased or hypertrophied heart for many reasons. They are plentiful in the cell, 
though most are bound in proteins and unavailable for immediate metabolism. 
This is particularly true during acute ischemia as proteolysis is decreased.2, 25 
The limited availability of myocardial proteins and the potential loss of function 
and increasing metabolic damage from free radicals and low pH create an 
important role for the provision of a blood-borne amino acid supply as a potential 
substrate for ATP formation in ischemic and hypertrophied hearts. It may be 
possible to improve recovery and maintain function by gaining a more thorough 
understanding of the role amino acids play in ischemia and hypertrophy.  
Cardiac ischemia, typically the result of the partial or complete occlusion 
of a coronary artery, is manifested as a fall in intracellular levels of ATP, 
glycogen, glutamate and aspartate and increased lactate production and alanine-
to-glutamate ratios. It has been proposed that supplementation with exogenous 
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glutamine, glutamate and aspartate may enhance cardiac metabolism when 
administered in the reperfusate after removal of coronary blockages.18-21, 36 
Amino acid supplementation may contribute to cardioprotection in several ways : 
1) anaplerosis of TCA intermediates, 2) elimination of inhibition of succinate-CoA 
reductase by oxaloacetate and increased substrate-level phosphorylation, 3) 
providing high levels of NADH and NADPH for rapid oxidation once oxygen 
returns and 4) the production of reduced glutathione, an antioxidant that can 
protect the heart from free radical damage.18, 37 
In a study by Julia et al., immature dog hearts were found to be more 
tolerant of ischemic conditions than mature hearts and also to contain higher 
intrinsic levels of glutamate.30 Other studies have shown that elevated levels of 
intracellular glutamate are at least partially responsible for the heart’s resistance 
to ischemic damage.18-20 Blockage of glutamate transamination using 
aminooxyacetic acid (AOA) inhibits glutamate and aspartate utilization and 
reduces the heart’s ability to recover from ischemic episodes. Specifically, the 
blockage of glutamate transamination in tissue homogenates resulted in an 
immediate decrease in lactate, alanine and succinate production, all of which 
should be produced by tissue homogenates. In the absence of AOA, the hearts 
were able to withstand 45 minutes of global ischemia, requiring no external 
stimuli to resume normal function and showing little or no ill effect from the 
prolonged insult. Administration of AOA, however, resulted in severe loss of 
function after the same period. It also resulted in much less lactate, alanine and 
succinate production, and much lower glutamate conversion.30 These results 
12 
 
demonstrate that cardiac function and long-term recovery require glutamate and 
aspartate transamination, while blockage of transamination results in decreased 
recovery and increased mortality.30 Cardiac transaminases are so prevalent, in 
fact, that their presence in the blood was diagnostic for heart damage for many 
years before troponin and creatine kinase tests. 
Glutamate and aspartate have very large muscle/plasma ratios, indicating 
that they are taken up into cells with high affinity. However, during ischemia the 
large concentration gradient leads to their release during ischemia25, 36 because 
of the loss of transporter function that normally maintains the gradient. Cardiac 
cells supplemented with excess glutamate show significantly increased 
NADH/NAD+ ratios and ATP levels in vitro. A fall in intracellular glutamate is 
associated with increased alanine production and decreased ATP concentrations 
after at least 10 minutes of ischemia.25, 37 Glutamate loading also improves the 
cells’ contractile activity and Ca2+ homeostasis after chemical hypoxia.36, 37 
Increased intracellular glutamate stores are correlated with improved metabolic 
recovery, increased cardiac output and elevated glutathione levels after an 
ischemic episode.18-20 
Ischemia significantly reduces the stores of tissue glutamate, ATP and 
glutathione while increasing lactate levels.18 In response to ischemia, the heart 
will significantly enhance alanine production and glutamate consumption, though 
these effects become significant only when the partial pressure of oxygen in the 
tissue falls to 5% of normal levels. While the uptake of glutamate does not 
directly correlate with alanine production and release, it is a contributor under 
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reduced oxygen conditions.24 Though glutamate is taken up by the heart, 
intracellular stores of the amino acid are readily transaminated with aspartate 
and alanine, allowing a greater storage and flux capacity than might otherwise be 
expected.25 Glutamate and glutamine may also work as reservoirs to protect 
against post-ischemic reduction in cardiac output by maintaining metabolic 
intermediates.29 Glutamate and glutamine are readily interconvertible in the heart 
and may serve as a means of controlling levels of TCA cycle intermediates via 
conversion of glutamate to α-ketoglutarate.20  
Glutamine supplementation prior to an ischemic event improves cardiac 
function and reduces free radical damage by improving ATP production and 
content, oxidative capacity and glutathione content.18, 20, 21 Studies have shown 
that glutamine supplementation significantly increases glutathione and reduces 
cardiac damage from surgery, toxins and presumably from transient ischemia as 
well.38, 39 Glutamine does not appear to activate heat shock proteins but it does 
increase myocardial COX-2 levels, which are associated with decreased infarct 
sizes and reduced ROS damage during reperfusion and subsequent ischemia.40 
Despite the evidence supporting the role of glutamate in the ischemic 
heart, it may not be clinically feasible to supply intravenous glutamate due to 
possible neural and cardiac toxicity at high plasma concentrations (20-70 mM).18 
A single dose of oral or intravenous glutamine was shown to improve tissue 
glutamate levels without the need for high levels of glutamate in the plasma.18, 19 
This is due to the presence of high-affinity transporters for glutamine in the heart, 
and a high level of glutaminase activity allowing the heart to rapidly convert 
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circulating glutamine into intracellular glutamate stores. The improved cardiac 
performance from glutamine has been seen with circulating glutamine levels as 
low as 1.25 mM, a level easily achieved by an oral dose of glutamine.18, 19 
Intracellular glutamate protects against loss of TCA cycle intermediates and 
improves post-ischemic oxidative metabolism, which may help to explain the 
increased ATP content in the glutamine-treated hearts. Glutamine 
supplementation increased post-ischemic phosphocreatine and NAD+/NADH 
content after ischemia and reperfusion while decreasing lactate production. 
Glutamine’s protective effects have been seen even when administered 18 hours 
before ischemia, though the effects are greater when administered 4 hours 
before ischemia.18, 19 This has important clinical implications as it has allowed 
cardiac surgeons to easily and reliably administer prophylactic glutamine 
treatments before surgeries.  
Glutamine cardioprotection is also associated with increased levels of 
UDP-GlcNAc and protein O-GlcNAc, nucleoplasmic proteins which have been 
shown to protect against ischemic injury and other damaging events.21 Blockage 
with azaserine and alloxan of the pathways that lead to the formation of these 
molecules eliminates the protection afforded by glutamine supplementation. 
Glutamine alone increased ATP levels three-fold after ischemia and reperfusion 
compared to controls, but the addition of azaserine and alloxan reversed this 
effect.21  
Conflicting reports about whether amino acid supplementation is actually 
cardioprotective may be attributed to the effects of differing K+, Na+ and H+ 
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gradients, which may vary widely across experimental preparations.36, 37 
Inclusion of aspartate, glutamate and glutamine in animal heart perfusates and 
cardioplegic solutions improves metabolic and functional recovery and elevates 
high-energy phosphate levels post-ischemia, and they have been used 
experimentally in cardioplegic solutions with good results.18, 19, 28, 41 Questions 
regarding the efficacy of these amino acids may arise from xenotypic differences, 
protocol incompatibility or the use of free acids vs. amino acid salts.36  
Another assumption is that perfused amino acids are readily available for 
intracellular functions, without regard to transporter activity. Glutamate has a very 
high rate of uptake in isolated cells, and this uptake is enhanced by anoxia. The 
cells are also able to establish intracellular glutamate stores against very high 
gradients.42 Rennie et al. explored the role of glutamine transporters in both 
cardiac and skeletal muscle and showed the beneficial effects of glutamine 
supplementation and possible mechanisms of glutamine uptake stimulation.12 A 
more general view of amino acid transporters and their distribution was taken by 
Malandro and Kilberg.43 
Despite an abundance of evidence showing that amino acid 
supplementation improved myocardial protection during ischemia and surgery, 
relatively little is known about endogenous amino acid metabolism or the exact 
mechanism of the cardioprotective effect. While the use of amino acid 
supplementation for cardioprotection has been explored, there are few studies 
addressing electrophysiological changes concomitant with the supplementation.  
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Data from human subjects with exercise-induced ischemia showed that 
these patients release significantly more alanine during cardiac ischemia and 
take up more glutamate than non-ischemic subjects.22 This has been seen in 
other model systems as well, indicating that this is a conserved process.25 
Changes in amino acid flux were seen not only during acute ischemic episodes, 
but for many days after the episode, indicating that bouts of acute ischemia 
induce biochemical changes that enhance the heart’s ability to utilize alternative 
substrates.  
Alanine is produced and secreted by the heart under almost all conditions, 
including hypoxia and ischemia. This has been demonstrated in patients with 
chronic ischemic heart disease25 and exercise-induced ischemia,22 as well as in 
hypoxic24 and ischemic36 heart tissues and insulin-clamped working hearts.23 
Large amounts of alanine can be found in hypoxic tissues, including the tissues 
of diving mammals and hypoxic skeletal muscle, especially in chronic ischemic 
heart disease. Taegtmeyer showed that alanine production was not significantly 
enhanced until the concentration of oxygen was decreased to less than 5%.24 In 
another study, glutamate supplementation had a negligible effect on papillary 
muscle alanine production in the presence of glucose in both aerobic and 
anaerobic conditions, and glutamate consumption was not enhanced until the 
oxygen concentration of the buffer was reduced to 5%.24, 37 L-cycloserine, an 
inhibitor of alanine aminotransferase, markedly decreased intracellular alanine 
and increased glutamate levels, even above baseline levels, showing that 
glutamate is not directly responsible for all of the observed alanine production, 
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although it is a contributor. This also indicates that alanine production is most 
likely due to glutamate/pyruvate transamination, but acute alanine production 
may not necessarily reflect the rate of glycolytic pyruvate production, since 
ischemia could be causing the release of intracellular stores of alanine.24, 30  
Pyruvate levels in the cell decrease by 50% during ischemia, and lactate 
levels in the surrounding media increase 27-fold after 20 minutes of ischemia.25 
Another study showed that increasing the levels of pyruvate in the media results 
in increased alanine production in both aerobic and anaerobic cells, indicating 
that substrates are the limiting factor in alanine production and supporting the 
idea that alanine is produced via transamination of pyruvate.30 In glucose-free 
media, lactate and alanine production is increased compared to normal media, 
and inhibition of glycolysis suppresses this production significantly.24 Ammonia is 
also produced by the deamination and deamidation of amino acids, and has 
been measured at 5.5 times normal levels during ischemia.25  
Though the addition of amino acids may improve metabolic function, it 
does not increase protein synthesis until amino acids are present at 5 times 
normal physiologic concentrations. Glycine, alanine and glutamate showed net 
myocardial release under non-ischemic insulin-supplemented conditions. The 
BCAAs leucine and isoleucine were taken up by the heart in a concentration-
dependent manner. No other amino acids showed significant uptake or release 
with or without insulin supplementation.23 It had been previously demonstrated 
that glutamine and asparagine were released and leucine and isoleucine were 
consumed in humans, though Schwartz et al. improved glutamine detection 
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methodology and revealed a higher rate of glutamine uptake than had been seen 
in earlier studies. Despite these findings, BCAA supplementation has shown 
negligible uptake or improved performance in subsequent studies of ischemia. 24, 
25, 36 
Any increased uptake of BCAAs likely results in a corresponding increase 
in their metabolism, since net protein synthesis is negligible over the course of an 
ischemic episode, and cellular concentrations would have been 2-4 times higher 
than the arterial concentration were they not metabolized. However, conversion 
to ketoacids or oxidation necessitates removal of amine groups from the BCAAs 
with no commensurate increase in alanine or glutamate, so it is unclear exactly 
how they are metabolized. Since these amino acids have several pathways 
through which they can be converted, the nitrogen may be lost through any 
number of metabolites which were not measured.23 
 
Amino Acids as Protein Precursors 
In the healthy heart, the aromatic amino acids (phenylalanine, tryptophan 
and tyrosine) are not metabolized.27 This makes these amino acids useful 
markers for protein turnover experiments, as any aromatic amino acid released 
from the heart must have come from proteolysis, and any aromatic amino acids 
taken up by the heart are almost certainly being incorporated into nascent 
protein.26 Protein turnover, however, is a balance between degradation and 
synthesis, so a zero net aromatic amino acid flux does not necessarily indicate a 
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lack of protein turnover, but rather a balance between proteolysis and protein 
synthesis. 
Studies of phenylalanine incorporation have shown that elevated levels of 
amino acids lead to greater protein synthesis.27 The human heart contains 
284±17 µmoles of phenylalanine per gram, and Morgan et al. saw that 1.24 
µmoles were incorporated in 90 minutes, indicating 14.3 days for complete 
protein turnover in vitro. In vivo turnover may be faster, since incorporation rates 
are lower in vitro than in vivo. The elevated rates of incorporation were not due to 
increased ATP levels, as an aggregation of ribosomes was seen, but there was 
no commensurate rise in the ATP/p-creatine ratio.27 
Another corollary between amino acid metabolism and ischemia is that 
long-term ischemia/damage is expected to result in increased proteolysis and 
contribute to the decline in long-term cardiac function after ischemia, though it 
should be noted that proteolysis decreases during acute ischemic episodes to 
12% of normal.25 In the presence of puromycin (a protein synthesis inhibitor), 
tyrosine was produced by cells under aerobic and anoxic conditions equally in 
the presence of 5 mM glucose. Alanine production was not affected by these 
conditions. Under anoxic conditions without puromycin, twice as much tyrosine 
was produced as under aerobic conditions, indicating an increase in the rate of 
proteolytic aromatic amino acid production.24 This means that protein 
degradation during oxygen deprivation should be manifested as an increase in 
the rate of aromatic amino acid release from the myocardium.  
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In an interesting study by Razeghi et al., a heterotopic anastomized heart 
model was used to simulate cardiac atrophy.44 The heart was removed from one 
rat and placed in another rat to create a cardiac bypass to decrease the load on 
the main heart, resulting in atrophy. Results showed proteolysis and protein 
synthesis occurring simultaneously in atrophic remodeling, rapidly in the first two 
days, peaking between 2-4 days and slowing considerably by 28 days. This 
demonstrates that remodeling requires activation of both degradative and 
synthetic pathways, but that the difference between the two would be manifested 
in an altered flux of the aromatic amino acids. These results can be extended to 
chronic ischemia, hypertrophy and several other conditions as there is increased 
protein synthesis, but also increased protein turnover, in long-term cardiac 
diseases.34 
 
Amino Acid Detection Methods 
Amino acid monitoring in the heart has historically been done by 
measuring the difference in amino acid concentrations between coronary arterial 
input and coronary venous output across the whole heart. This, of course, is 
insufficiently precise for current studies, and many methods are now in use for 
precisely quantifying the amino acid flux in the myocardium, as well as identifying 
the metabolic fates of the molecules. 
The most accurate and widely used amino acid monitoring technique is 
the radiolabeled tracer study.42, 45, 46 These labels can be detected with positron 
emission tomography (PET) for imaging amino acid accumulation in the tissues 
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as well as quantifying media depletion in a culture setting. Similarly, NMR studies 
detect the labels and can track the labeled carbon or nitrogen through its many 
conversions to determine how the amino acid was metabolized.47 Mass 
spectrometry is also a common method of quantifying amino acid flux, as it is 
highly sensitive to even small changes in concentration and is capable of very 
rapid processing of large numbers of samples.48 It has the additional benefit of 
being highly adaptable to pre-separation protocols like gas chromatography and 
ion mobility mass spectrometry.49-53  
Unfortunately, once amino acids enter the TCA cycle carbon labeling 
becomes much more difficult to track, as the carbons are fungible. The 
appearance of labeled CO2 is highly indicative of amino acid oxidation, but it 
does not necessarily mean that the entire amino acid has been oxidized or that 
the conversion was direct, since there are many paths that feed into and out of 
the TCA cycle. Nitrogen labeling is reliable insofar as oxidized amino acids must 
release NH3, but there are many ammonia acceptors within the cell. Often the 
amine is transferred to pyruvate to form alanine or α-ketoglutarate to form 
glutamate and glutamine, but this is not always the case.45  
 
Current Medical Interventions 
Heart failure is caused by an imbalance in supply and demand, and often 
the deficit is in oxygen supply. Interventions that shift metabolism away from fatty 
acids to substrates with greater ATP produced/O2 consumed ratios will have anti-
anginal effects. Current medical treatments focus primarily on increasing cardiac 
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output and decreasing afterload, but few treatments attempt to rectify the 
underlying metabolic dysfunction of the failing or ischemic heart. Medications 
focus on lowering blood pressure, fluid retention and cardiac work to relieve 
symptoms of acute and chronic heart failure while the accompanying alterations 
in cardiac metabolism are left untreated. A few drugs for treatment of the 
metabolic disease state – for example, trimetazidine – have been developed 
recently to treat the underlying metabolic disease state instead of just the 
symptoms and have shown promise.54, 55 We need to continue learning more 
about cardiac metabolism if we wish to effectively treat the underlying metabolic 
derangement. We must understand in detail how changes in metabolic substrate 
affect electrophysiology, and we need to find new ways to optimize the heart’s 
fuel usage and minimize the damage incurred by transient ischemia if we want to 
turn the tide in the battle against heart disease. 
 
Conclusion 
The fact that amino acids are not only protein precursors but can also be 
metabolites, neurotransmitters and antioxidants makes them ideal candidates for 
determination of underlying cellular functioning in the age of metabolomics. It is 
already clear that uptake and release of certain amino acids can give a great 
deal of information about intracellular processes. Even without looking inside the 
cell, it is recognized that if tyrosine, phenylalanine or tryptophan show net uptake 
by cardiomyocytes over a period of days or weeks, then they are being 
incorporated into new proteins. This would indicate not simply protein turnover, 
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but an increase in the total protein pool. Such information can be used to 
determine the effects of pharmacologic agents or other interventions that perturb 
normal cell function. 
Computational models of cardiac myocyte excitation are beginning to 
include contraction and energy metabolism.56-58 However, we believe that these 
models need also to include amino acid pathways and fluxes to accurately model 
the metabolic events that accompany both chronic and acute ischemia and other 
diseased states of the heart. Such models would also benefit from the inclusion 
of models of intracellular pH regulation, as it is associated with ischemia and 
affects many metabolic reactions.  
The versatility of amino acids makes them ubiquitous across all cells and 
tissues. If alterations in amino acid flux can be linked to abnormal cell behavior, 
tools to monitor amino acid flux could serve to evaluate tissue viability. If, for 
example, a donor heart could be transported with an amino acid detector, its 
health could be monitored in transit, and transplant surgeons would have a better 
understanding of its viability and more information about its expected longevity 
once it is implanted. If the heart displays characteristics associated with 
starvation or stress, then special interventions may be needed to improve its 
condition before it is implanted. This scenario is still not possible, but with 
advances in metabolic monitoring, it becomes a very real possibility in the not-
too-distant future. 
In summary, we have reviewed the import of the role of amino acid 
metabolism in the normal and failing heart. Our review of the literature would 
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suggest that additional research is required to understand how amino acid 
supplementation affects not only the metabolic but also the mechanical and 
electrical performance of the heart. It is hoped that this review clearly illustrates 
the need to unite the disparate fields of electrophysiology and metabolism to 











MATERIALS AND METHODS 
 
Introduction 
Since there is a great deal of overlap in the materials and methods used 
throughout my experiments, I have chosen to describe them in a dedicated 
chapter of this thesis to save time and space. This will also facilitate discussion of 
the distinctions between methodologies as they can be discussed together in one 
section instead of across separate chapters. 
 
Animal Care and Surgery 
All experiments conformed to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health (NIH) and 
were approved in advance by the Vanderbilt Institutional Animal Care and Use 
Committee. Animals were housed for between 1 and 14 days in the Vanderbilt 
Division of Animal Care. They were given food and water ad libitum. 
New Zealand white rabbits of either sex weighing 2.7 to 3.1 kg were used 
in the experiments. On the day of the experiment, animals were randomly 
assigned to either the control or experimental groups using a coin toss decision. 
Before surgery, the animals were preanesthetized with ketamine (50 mg/kg), 
heparinized (1,000 units) and anesthetized with sodium pentobarbital (60 mg/kg) 
via a left ear vein.  
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Upon failure to respond to the paw pinch and eye reflex tests, the animals’ 
chests were opened by midsternal incision and radical medial thoracotomy. The 
hearts were quickly removed from the chest and the aorta cannulated on a 
temporary Langendorff apparatus (LA) located above a sink immediately 
adjacent to the surgical table.  
 
Experimental Preparation 
On the temporary LA the aorta was sutured tightly to a cannula mounted 
in a square plexiglass frame (Figure 2-1). The LA perfuses the coronary arteries 
with oxygenated Tyrode's solution of the following composition (mM): 133 NaCl, 
4 KCl, 2 CaCl2, 1 MgCl2, 1.5 NaH2PO4, 20 NaHCO3, and 10 D-glucose, buffered 
with 95% O2 and 5% CO2 (pH = 7.35 at 37°C). Hearts assigned to the amino acid 
supplemented group received the Tyrode’s solution supplemented with 2.5 mM 
glutamine and 150 μM glutamate. Hearts assigned to the aminooxyacetate 









A small suture was placed very shallowly in the apex of the heart. This 
suture was tied loosely but firmly so as to not cause localized ischemia but 
remain secure. In the apical suture a 1-2” length of rubber band was tied. This 
was threaded through a hole in the plexiglass framework below the heart and 
pulled just tight enough to remove all slack from the band. The band’s tension 
was maintained by means of a clip on the framework. This apical tension 
reduced motion of the heart and prevented it from floating when placed in a 
media bath. For experiments involving ischemia, a small puncture was made in 
the bottom of the left ventricle (LV) near the apical suture using small surgical 
scissors to breach the epicardium and a 12 gauge needle to puncture the 
endocardium. The needle remained in the LV to act as a shunt in case of aortic 
  
Figure 2-1. Heart stabilization and ECG frame. A rectangular plexiglass frame 
allowed for flexible anchoring of the heart to reduce movement. A rubber band 
is sutured to the apex of the heart and gently anchored to the bottom of the 
frame to reduce motion and counter the natural buoyancy of the heart. 
28 
 
valve regurgitation and LV inflation. This was not necessary during anoxia 
experiments since perfusion pressure remains constant, whereas ischemia 
experiments require pumps to turn on and off, leading to possible spikes in 
perfusion pressure. 
Once the sutures and shunt were properly placed the plexiglass 
framework and cannulated heart were quickly moved to a permanent LA (Figure 
2-2) located in a Faraday shield maintained at 37 ± 0.5°C by a precision heater 
controller (Air-Therm, World Precision Instruments, Sarasota, FL). The 
 
Figure 2-2. Anoxia Langendorff perfusion apparatus. Two graduated cylinders 
were filled with media, one oxygenated and the other deoxygenated. Anoxia 
and recovery were caused by switching from one media source to the other. 
The MAP probe (orange circle) was placed on the septum (curved black line 
on the heart). 
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permanent LA had increased experimental capacity as well as superior thermal 
and media handling capabilities. The coronary perfusion pressure was adjusted 
to 50 mmHg and the flow rate was 44 – 49 ml/min. To ensure that all hearts were 
performing equal amounts of work we applied an external pacing electrode, and 
the pacing stimulation was maintained at a cycle length of 300 ms delivered via a 
bipolar glass-coated platinum electrode (0.25 mm wire diameter; 1 mm electrode 
separation) located on the anterior surface of the right ventricle near the septum. 
The stimulus was 4 ms in duration for anoxia experiments and 10 ms for 
ischemia experiments, and the amplitudes were adjusted to between 2-10 mA 
depending on the excitation threshold of the heart throughout the experiment.  
Anoxia experiments were conducted without immersing the heart in a 
media bath since the constant flow of perfusate adequately heats the heart and 
prevents dessication (Figure 2-2). For ischemia experiments, however, cessation 
of flow raises the possibility of cardiac hypothermia and dessication so a media 
bath is required (Figure 2-3). The media bath’s temperature and circulation are 
maintained by a separate media source and external circulatory pump.  
 
Study Protocol 
The standard method of experimental design for cardiac experiments 
began with unknown intervention duration and unknown recovery duration for a 
drug treatment with unknown dosage.  We began by challenging hearts with 
increasing intensity or duration of the challenge to adequately tax the heart 
without causing irreversible damage.  We wanted to see reduced performance 
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that resulted in moderately depressed long-term performance in the untreated 
group.  This is a difficult problem since the heart is a resilient organ with a variety 
of compensatory mechanisms to maintain cardiac output.  Many challenges 
result in acute loss of function with complete recovery almost immediately. On 
the other hand, an over-taxing challenge results in irreparable declines in cardiac 
function resulting in cardiac death. There is also the issue of cardiac 
preconditioning where an initial challenge prepares the heart for subsequent 
 
Figure 2-3. Ischemia Langendorff perfusion apparatus. A single media source 
was continuously bubbled with oxygen, and ischemia was induced by 
stopping the pump and clamping the line above the water jacket to eliminate 
perfusion normally driven by the head pressure of the water column. Voltage-
sensitive dye was added to the perfusate via a bubble trap located above the 
heart. The media bath was heated by continuously circulating the media 
through an external heater (not shown). 
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challenges and increases its tolerance.  This may result in a given challenge 
being mislabeled as lethal or non-lethal simply due to its order in the experiment. 
 Once a satisfactory treatment dosage is established, we need to test the 
effective concentration of a drug or metabolite.  The heart will theoretically reach 
a toxicity threshold and cardiac function will suffer.  This decrease in function 
may or may not be the result of the treatment since the heart may be responding 
to external factors such as the duration of the surgery or the amount of time the 
heart has been hanging.  We may also have been far below or above the 
treatment threshold, necessitating further experiments to test this possibility. 
 Duration of recovery is somewhat easier to determine since there is no 
limit to how long the heart can be allowed to recover.  We simply monitor 
recovery and find the point at which the heart reaches a new steady state (+/- 
5%) for about 5 minutes.   
 
Anoxia 
The timeline of the anoxia experiments is shown in Figure 2-4. Hearts 
were placed on the LA and allowed to acclimate to perfusion and pacing for 30-
40 minutes. Once the hearts were stable, baseline APD measurements were 
taken every 4 minutes for 20 minutes. The heart was then switched from O2-
bubbled media to N2-bubbled media. Measurements were taken every minute for 
the 6-minute anoxic episode. After 6 minutes the hearts were returned to 
oxygenated media for 20 minutes, with measurements taken every minute for 6 
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minutes, every 2 minutes for the next 6 minutes and then at 15 minutes and 20 
minutes post-anoxia. The anoxia and recovery cycle was then repeated. 
 
Ischemia 
 The timeline of the ischemia experiments was similar to that of the anoxia 
with a few crucial differences (Figure 2-5). We used three consecutive challenges 
instead of two and extended the insult from 6 minutes to 10. We also added a 
shunt to the LV to reduce ventricular hyperinflation and maintained the hearts in 
a media bath to maintain temperature and hydration throughout the experiment. 
 Ischemia was induced by turning off the perfusion pump and clamping the 
perfusate line that maintains perfusion pressure. The head pressure line must be 
clamped to eliminate perfusion from the pressure of the water column. Flow is 
 
Figure 2-4. Timeline of an anoxia experiment. Anoxia episodes lasted for 6 
minutes each, and the baseline and recovery periods were 20 minutes each. 
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Figure 2-5. Timeline of an ischemia experiment. Ischemic episodes lasted for 
10 minutes each, and the baseline and recovery periods were 20 minutes 
each. 
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returned by removing the clamp and turning the pump on at very low speed for 
30 seconds before returning to operating speed. This low initial flow rate 
eliminates pressure transients on pump startup that can overpressurize the LV 
and potentially damage the aortic valve. 
 After the experiments, the hearts were frozen at -80°C within 5 minutes of 
the end of the experiment. The frozen hearts were then sent to the Vanderbilt 
laboratory of Dr. Jackson Roberts for isoprostane and isoketal analysis. 
 
APD Measurement Techniques 
MAP Probe 
 A monophasic action potential (MAP) was recorded using a commercially 
available standard MAP catheter (1675P, EP Technologies) (Figure 2-6). While 
MAP is an extracellularly recorded wave form, it closely reproduces the course of 
the repolarization phase of the transmembrane action potential and has been 
broadly utilized in both clinical and experimental conditions to obtain stable 
recordings to monitor APD 59-62. The MAP probe was positioned on the 
epicardium close to the septum on the anterior side of the heart and held 
perpendicular to the surface. The signals were amplified with a differential 
amplifier (DP-301; Warner Instruments, LLC, Hamden, CT) and then visualized 




Optical Fluorescence Detection 
 For the ischemia experiments we adopted an optical voltage detection 
method that was already in use in the lab.63, 64 This decision was made for 
several reasons: 
1) The need to keep the heart warm in a media bath made the MAP probe 
unfeasible due to space constraints in the bath. 
2) The MAP probe was prone to signal decay due to localized ischemia from 
the pressure of the probe and movement of the probe on the surface of 
the beating heart. 
 
Figure 2-6. MAP Probe Illustration. The MAP probe measures the 
transmembrane potential of ~5 mm2 of the epicardium by pressing an 
electrode against the epicardium and comparing it to a reference electrode. 
The pacing electrodes were not used in these experiments. Image from Franz 
MR. Cardiovasc Res (1999) 41 (1): 25-40. 
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3) Use of the MAP probe restricts data acquisition to a single location directly 
under the probe. If the location proves substandard during data analysis, 
there is no way to choose a new point. 
For ischemia experiments the hearts were stained with a voltage-sensitive 
dye called di-4-ANEPPS (Invitrogen Co, Carlsbad, CA, USA) stock solution (0.5 
mg/ml dimethyl sulfoxide) administered via a bubble trap above the aorta and 
allowed to equilibrate for 5 minutes.  
The anterior LV was illuminated by 532 nm laser light (Verdi, Coherent, 
Santa Clara, CA, USA). The emitted light passed through a cutoff filter (no. 25 
Red, 607 nm, Tiffen, Hauppauge, NY, USA) and was imaged with a CCD camera 
(Model CA D1-0128T, Dalsa, Waterloo, ON, Canada) with spatial and temporal 
resolution of 128 ×128 pixels and 500-1000 frames s−1. Custom-developed data 
acquisition software using LabVIEW (National Instruments, Austin, TX, USA) and 
MATLAB was used to record and analyze the data. 
 
Action Potential Duration Analysis 
There are two types of APD data collected in these experiments: MAP 
probe data collected on an oscilloscope for anoxia experiments and optical data 
collected on a PC for ischemia experiments. Both types of data are processed 
using MATLAB software and plotted in Microsoft Excel spreadsheets, but the 





The MAP data were analyzed using MATLAB software to measure APD. 
APD was calculated by finding dV/dtmax and measuring the length of time for the 
action potential to return to 90% (APD90) repolarization (Figure 2-7). Each time 
point is the average APD of 6-8 sequential action potentials taken in series. 
 
Ischemia 
In MATLAB the optical data are analyzed using algorithms written by 
Raghav Venkataraman, a former graduate student in the lab of our collaborator 
Franz Baudenbacher, and various lab personnel. The data are visualized using 
 
Figure 2-7. MAP probe APD calculation. Action potential duration was 
calculated from the point of maximal rate of depolarization (dV/dt max) to the 
point when the potential was 10% of the maximum action potential amplitude 
(APD90). Each measurement consisted of 6-8 sequential action potentials, and 
the results were averaged for each measurement with a single baseline and 
maximum amplitude used for all AP’s in the measurement as shown here. 
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an algorithm titled “Gus2” written by Gustavo Rohde, a former Vanderbilt 
undergraduate and graduate student. The data was then analyzed by another 
algorithm called “APDClicker” written by Raghav Venkataraman, another former 
Vanderbilt graduate student (Figure 2-8). APDClicker allows the user to choose 
any pixel on the 128x128 pixel image to analyze. This algorithm then calculates 
baseline voltage, dV/dtmax and APD50, APD70 and APD90 for each action potential 
independently in the 5x5 pixel area around the selected point (Figure 2-9). 
Independent AP calculation is important as it reduces the impact of signal drift, 
alternans and inter-beat variability (Figure 2-10). APDClicker data are then 
exported to Microsoft Excel for further statistical analysis and modeling.The 
selection of the proper location for APD analysis requires minimal motion artifacts 
for proper APD calculation. The region chosen for our experiments was on the  
 
Figure 2-8. A. Data display of the “Gus2” analysis software showing action 
potentials averaged over a selected area of the heart  B. “APDClicker” action 





Figure 2-9. Optical APD calculation. APD was calculated from the point of 
maximal rate of depolarization (dV/dt max) to three points of the restitution 
curve: 50% (APD50), 30% (APD70), and 10% (APD90) of the maximum AP 
amplitude. Each measurement consisted of 6-8 sequential action potentials 
and the results were averaged for each measurement. This figure shows only 
three action potentials for illustrative purposes and simplicity. 
 
Figure 2-10. Motion and trend compensation in the “APDClicker” software. 
This trace had a slow baseline drift that does not appear in the final data due 
to independent baseline correction for each AP. 
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epicardium closest to the septum of the heart approximately halfway between the 
apex and the atria (Figure 2-11). The septum was chosen due to its relative 
stability (compared to the LV’s motion) and its high level of activity and response 
to challenge (compared to the RV’s quiescence and resilience). The center of the 
septum was chosen as a compromise between the pendulum-like motion of the 
apex and the complex anatomy around the top of the heart. This area in the 
center of the heart is also held steady by light pressure against the front wall of 
the media bath, further reducing motion artifacts in the region. These parameters 
limit the region of interest to an area approximately 20x40 pixels. The user then 
Figure 2-11. Comparison of the right and left ventricle for ischemic imaging. 
The red circle indicates the location of the MAP probe on the surface of the 
heart adjacent to the septum. Selection of a point on the surface averages the 
fluorescence of a 5x5 pixel area and displays the intensity over time. 
40 
 
finds a pixel in this region with minimal motion, which manifests as a lack of 
steady baseline, spikes or peaks in the action potential plateau or multiple 
identified “action potentials” in a single pacing interval (Figure 2-12). 
 
Isoprostane and Isofuran Quantification 
Frozen hearts were sectioned for isoprostane and isofuran analysis by first 
discarding approximately 2 g of tissue from the apex. This was done to remove 
any tissues that may have been damaged or suffered ischemia from the apical 
suture. A section of the left ventricular wall measuring approximately 0.5 cm by 
 
Figure 2-12. Identical points on the surface during perfusion and ischemia. 
During ischemia, the intraventricular pressure drops and the heart becomes 




0.5 cm was then removed and sent to Dr. Jackson Roberts’s lab for isoprostane 
and isofuran analysis. 
To test for isoprostanes and isofurans, the frozen sections were first 
added to a Folch solution (2:1 chloroform:methanol) containing 5 mg/100 ml 
butylated hydroxytoluene (BHT) at 20 ml/g of tissue in a conical tube and placed 
on ice. Tissues were then homogenized and the tubes sealed in nitrogen and 
allowed to sit at room temperature for 1 hour with occasional vortexing. A 0.9% 
NaCl solution was then added at 4 ml/1 g tissue and vortexed for 1 minute. The 
tubes were then centrifuged at 2000 rpm for 5 minutes to produce two layers. 
The upper aqueous layer was discarded and the organic layer transferred to a 
fresh tube. The organic liquids were dried under N2 at 37°C 
Depending on the amount of lipid present, 0.5-2 ml MeOH containing 5 
mg/100 ml and an equal volume of 15% KOH was added. Samples were 
vortexed and, after the sides of the tube were scraped to suspend any adhered 
material, let sit at 37°C for 30 minutes. The pH was brought to ~7.0 with 1N HCl 
and then diluted to 10-40 ml with deionized water. Dilutions were made such that 
the volume of resuspension MeOH was less than or equal to 5% of the total 
volume. 1 ng of deuterated (d4) F2-isoprostane internal standard was added to 
~1 ml deionized water, vortexed and transferred to each sample tube and mixed 
well by gently inverting the tubes. Samples were brought to ~pH3 with 1 N HCl 
and placed on ice for the free F2-Isoprostane assay. 
A C18 Sep-Pak was attached to a 12cc syringe and pre-conditioned with 5 
ml MeOH and 7 ml pH 3 deionized water. Samples were then slowly pushed 
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through the Sep-Pak at ~1-2 ml/min. Samples were then washed by running 10 
ml of pH 3 water and then 10 ml of heptane through the Sep-Pak. Samples were 
eluted from the Sep-Pak with 10 ml of 1:1 ethyl acetate:heptane into 20 ml 
scintillation vials. A small scoop of sodium sulfate was used to remove any 
remaining water. 
A new silica Sep-Pak was then pre-rinsed with 5 ml ethyl acetate and 
placed on the syringe. The sample from the scintillation vial was then slowly run 
through the Sep-Pak, being careful not to transfer any sodium sulfate, and 
washed with 5 ml ethyl acetate. Samples were eluted from the silica Sep-Pak 
with 5 ml 1:1 ethyl acetate:methanol into a 5 ml reactivial and dried under N2 at 
37°C. 
Samples were esterified by adding 40 µl 10% pentafluorobenzyl bromide 
(PFBB) solution in acetonitrile (ACN) and 20 µl 10% diisopropylethylamine 
(DIPE) in ACN, vortexing and incubating at 37°C for 20 minutes. Samples were 
then dried under N2 and reconstituted in 50 µl 3:2 methanol:chloroform. 
 The samples were purified using thin-layer chromatography (TLC) as 50 µl 
of sample were spotted on a TLC plate and allowed to separate in a solvent 
system consisting of 93% chloroform and 7% ethanol. The PGF2a TLC standard 
was measured and the area containing the desired bands was scraped onto a 
piece of creased weighing paper and poured into a microcentifuge tube. 1ml of 
85% ethyl acetate 15% ethanol was added and vortexed to resuspend the solids.  
Purified samples were then centrifuged for 2 minutes at 14,000 rpm and 
the ethyl acetate/ethanol was transferred into another centrifuge tube to remove 
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any silica solids and dried under N2 at 37°C. 20ul BSTFA and 8 ul of dry (CaH2 
added) dimethylformamide (DMF) was then added to silate the samples for gas 
chromatography. Samples were again dried under N2 and reconstituted in 10-20 
ul dry (CaH2 added) undecane the day of GC/MS analysis. 
For the GC/MS separation a 15 meter DB 1701 GC column was used at 
an inlet temperature of 2600 and helium carrier gas at a flow rate of 2 ml/minute. 
For each sample injected, the GC oven was programmed to run from 1900 to 
3000 at 200/minute for 9 minutes. Samples were analyzed by selected ion 
 
Figure 2-13. Isoprostane quantification. Ions monitored were m/z 569 for F2-
Isoprostanes, m/z 585 for Isofurans, and m/z 573 for the internal standard d4 
15-F2t-Isoprostane. Yellow areas indicate the area of the peak used to 
quantify isoprostane content of the samples. 
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monitoring GC/NICI/MS. Ions monitored were m/z 569 for F2-Isoprostanes, m/z 




The statistical methods were previously published65 and summarized here.  
Action potential duration was modeled as follows:    ( ) =    +
  [  ( ) −   ( )] −    
 , where    is the baseline APD, and   ( ) and   ( ) are 
solutions to a pair of piecewise linear differential equations taking the form   
  =
−     during anoxia, and   
  =   (1 −   ) otherwise, for   = 1,2 and   (0) =
	  (0) = 1. Thus the effect of anoxia on APD was modeled as an exponential 
decay, followed by exponential recovery upon reoxygenation. Whereas   
  	enters 
the anoxia state immediately,   
   remains in the baseline state for a period of time 
determined by an offset parameter. This offsetting captures the transient 
elongation of APD just after the start of anoxia. The last term,    
 , models the 
secular trend (decay) in APD over the entire experiment. Nonlinear mixed effects 
regression66 was used to account for the variability among hearts (random 
effects), and to quantify the effects of amino acid supplementation (fixed effects) 
on each of the model parameters and the resulting APD in response to anoxia 
challenges. The mixed-effects method is similar to a “two-stage approach”, in 
which the statistical model is fitted separately for each heart (stage 1), and the 
resulting model fits or their summaries are compared across treatment groups 
(stage 2). While simple, this approach fails to “propagate” statistical uncertainty 
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to the second stage, and cannot be used when only partial data are available for 
some hearts. The mixed-effects method combines the steps of the two-stage 
approach for a parsimonious solution. The differences in the average APD 
between groups over the course of the experiment were summarized using 95% 
confidence intervals (confidence band). Intervals that exclude the appropriate null 
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Introduction 
Cardiac hypoxia/anoxia occurs during heart failure, carbon monoxide 
poisoning, drowning and other events where oxygen supply is interrupted without 
blockage of coronary arteries. While cardiac hypoxia/anoxia may not be as 
common or clinically applicable as cardiac ischemia, it allows dissection, and 
study of the physiological effects particularly related to oxygen deprivation 
without the sequelae associated with complete ischemia. During hypoxia/anoxia 
the heart receives adequate substrate throughput, and the blockage of oxidative 
phosphorylation can be isolated from the effects of waste accumulation or 
substrate depletion, as occur with no-flow ischemia.  
Glucose, fatty acids, and other substrates require oxygen for full energy 
yield and produce significant levels of acidic by-products 68. Amino acids are of 
particular interest due to their potential for nonoxidative metabolism and their low 
contribution to cellular acidification. In addition to their role as protein precursors, 
amino acids are essential components in many aspects of physiology and can 
serve as metabolic substrates 69. We hypothesized that supplementation with 
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glutamate and glutamine maintains electrical properties of the heart during 
anoxia and improves electrical stability in the recovery period. 
Glutamine and glutamate were chosen because glutamate can be easily 
transaminated to α-ketoglutarate and metabolized via the TCA cycle.70 It is also a 
one-step transamidation reaction to turn glutamine into glutamate, making the 
two amino acids highly interconvertible in the cell.71 Once the amino acids enter 
the TCA cycle as α-ketoglutarate, they can be converted to succinate, yielding 
one molecule each of GTP and NADH.30 This process does not require any 
oxygen and does not contribute to cellular acidification. This anaplerotic reaction 
also serves to maintain the levels of TCA cycle intermediates so that the 
metabolic machinery is primed to resume normal function once oxygen returns. 
To determine the effects of amino acid supplementation on the heart, we 
monitored the action potential duration (APD) of the heart in response to cardiac 
anoxia. APD is defined as the amount of time that the cell membranes remain 
above a given threshold, thereby enabling various ion channels to open or close 
to allow for the contraction of the muscle fibers. This particular parameter was 
chosen due to its importance as the linkage between cardiac metabolism and 
electrical function. Strictly metabolic readouts like ATP/ADP or NADH/NAD+ 
ratios may not directly correlate with cardiac output, and a functional readout like 
ejection fraction is an aggregate readout of various metabolic and environmental 
inputs. Using APD as a readout, we are monitoring first-order effects of the 
metabolic state without any intermediate reactions to complicate the signal. In an 
isolated paced heart we remove many of the biochemical and neural signals that 
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control cardiac function and define the metabolic components being supplied to 
the heart, thus minimizing the number of variables that can affect APD.  
In this study we subjected the hearts to repeated episodes of anoxia to 
elicit adaptive metabolic responses to the stressor. Six minutes of anoxia were 
found to result in a small but significant decrease in APD without inducing 
fibrillation or a loss of pacing. While glutamine and glutamate have been shown 
to improve outcomes when given to perioperative heart surgery patients39, 41 it is 
possible that prophylactic doses of glutamine may reduce the damage from 
transient anoxia or ischemia with few apparent side effects in populations at risk 
for cardiovascular events.  
 
Preliminary Data 
Initial experiments focused on identifying optimal experimental parameters for 
anoxia and recovery periods. Initial experiments used four, six, eight and ten 
minute anoxic challenges followed by 30 minute recovery periods. Our criteria for  
 optimal anoxia duration were: 
 1) APD depression during anoxia. 
2) Moderate APD depression during recovery.  
3) Equilibration at a steady APD during recovery.  
4) Survival of the heart for the entirety of the experiment. 
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Four minutes of anoxia was found to result in minor APD depression 
during anoxia with a rapid return to baseline APD (Figure 3-1). There did not 
appear to be a significant difference between the baseline and recovery periods. 
Eight minutes of anoxia resulted in severe APD depression during anoxia and 
recovery, frequently with arrhythmia and occasionally with cardiac death. This 
effect was even more severe after ten minutes of anoxia and every challenge 
resulted in arrhythmia and irreversible APD decline followed by cardiac death. 
We found that a six minute anoxia challenge resulted in significant APD 
depression during anoxia and a moderate decrease in APD during the recovery 
period. The APD decrease after six minutes of anoxia was found to be 
maintained for long periods after the challenge and the APD neither increased to 
pre-anoxia levels nor decreased beyond the post-anoxia steady state (Figure 3-
2). These preliminary studies also showed that the hearts had no additional 
 
Figure 3-1. Preliminary studies of various durations of anoxia challenge. A. 
Four-minute anoxia. B. Six-minute anoxia. C. Eight-minute anoxia. Increasing 
the duration of anoxia markedly lowers APD in the recovery period, and 
anoxia lasting eight minutes or longer leads to an irreversible progressive 
decline in APD. 
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changes in APD after 20 minutes of recovery, so this was chosen as an 
adequate time to allow the hearts to re-equilibrate after each anoxic episode.  
There has been a great deal of attention paid to the phenomena of 
ischemic preconditioning wherein a heart exposed to a short episode of ischemia 
will suffer much less damage when exposed to subsequent, longer ischemias. 
There has not, to our knowledge, been a similar study of anoxic preconditioning 
so we decided to investigate this phenomena ourselves. Indeed, we found that 
 
Figure 3-2. APD after a single anoxia. A total of 4 hearts (2 normal, 2 
enriched) were exposed to a single six-minute episode of anoxia. To roughly 
account for baseline variation among hearts we normalized the hearts to a 
percent of the APD at time 0. A single anoxia has a minimal effect on APD and 


































anoxia challenges given in series were found to elicit smaller effects from 
subsequent bouts of anoxia (Figure 3-3). An initial challenge of four minutes 
results in only minor APD decreases when followed by a six minute challenge. 
An initial challenge of six minutes results in significant APD decreases but the 
subsequent six minute challenge results in a much smaller APD decrease. 
 
Figure 3-3. Initial anoxia challenges decrease the effects of subsequent 
challenges. A. An initial four-minute challenge results in no significant APD 
depression. A subsequent six-minute challenge results in only minor APD 
decrease. B. An initial six-minute challenge results in significant APD decline, 
while the next challenge results in a much smaller APD decrease, though this 
could be due to the lower APD at the beginning of the second challenge. 
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Using the sequential anoxia challenge described above, we exposed 
amino acid enriched hearts to an initial challenge of four minutes and a 
subsequent challenge of eight minutes which had previously been shown to be 
highly damaging to the hearts with profound effects on APD. The amino acid 
concentrations (2500 µM gln, 150 µM glu) were significantly higher than normal 
plasma levels but not beyond what could be induced by IV supplementation or 
 
Figure 3-4. Hearts perfused with enriched media tolerate longer periods of 
anoxia. Hearts perfused with normal (top right) or enriched (bottom right) 
media were exposed to a four-minute anoxia challenge (left, representative 
image for both conditions) and then a subsequent challenge.  The hearts 
perfused with enriched media showed approximately equal APD recovery to 




even by consumption of oral amino acid supplements. 72-74 We saw that the 
enriched hearts suffered only moderate APD depression and had no arrhythmias 
even at the end of the eight minute anoxia (Figure 3-4). This was highly 
encouraging and we decided to test this phenomenon as a full scale experiment. 
 
Results 
In one set of experiments the heart was initially perfused with regular Tyrode’s 
solution for 20 minutes, and then the perfusion system was switched to supply 
the heart with enriched Tyrode’s solution for the next 20 minutes. The addition of 
 
Figure 3-5. APD stability during a long recovery phase after single anoxia. For 
each experimental replicate (N = 6), the APD time series is illustrated in light 
gray. For the purpose of graphical presentation, each original time series was 
adjusted to the overall pre-anoxia mean. The solid black line represents mean 
APD from the fitted model. The dotted black lines define a pointwise 95% 




amino acids insignificantly increased APD from 150.5 ms (95% CI: [148.5 ms, 
152.4 ms]) to 153 ms (95% CI: [149.9 ms, 156.1 ms]) (N = 24) (6 experiments, 
unpaired t-test). Another set of experiments (N = 5), wherein the hearts were 
exposed only to one anoxia, is presented in Figure 3-5. As the figure illustrates, 
mean APD recovers to 99% (152.7 ms, 95% CI: [148.3 ms, 157.0 ms]) of 
baseline APD within 10 minutes following cessation of anoxia; therefore, 20 
minutes was chosen as a sufficient recovery interval between two sequential 
anoxias.  
Figure 3-6 demonstrates the characteristic data of APD change in 
response to two successive anoxias. In this control experiment the heart was 
perfused with only glucose-containing media. Three phases can be readily 
distinguished in each set of anoxia. The first phase of abrupt APD increase starts 
immediately after onset of anoxia. This initial change in APD was more 
pronounced in the first insult of anoxia and was observed in 18 out of 21 
conducted experiments. The first transient phase is followed by considerable 
APD decrease, which lasts until cessation of anoxia. This APD shortening was 
always greater during the second period of anoxia. The third phase of anoxia-
induced change in APD takes place after recommencing the perfusion with 
oxygenated solution. The fast APD recovery phase continues for about 10 
minutes. The insets in Figure 3-6 illustrate MAP traces recorded at different 
phases of APD change. The described APD dynamics were typical in both 
control and hearts perfused with enriched media.  
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Figure 3-7 represents the effect of glutamine/glutamate supplementation 
on mean APD dynamics in response to two insults of anoxia (N = 16). The upper 
panel in Figure 3-7 illustrates estimated mean APD curves from control (blue) 
and from experimental (orange) hearts with individual time series data 
superimposed in lighter color. The lower panel shows the estimated difference in 
 
Figure 3-6. A typical double anoxia experiment. Two successive six-minute 
anoxic periods followed by 20 minutes of recovery. The insets demonstrate 
MAP recorded at different phases of anoxia-induced APD change. 
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mean APD between control and enriched groups and the 95% confidence band. 
After onset of the first anoxia, the first phase of acute transient APD increase 
peaks at 2.27 min (95% CI: [2.01min, 2.54 min]) with amplitude of 13.7 ms (95% 
CI: [11.8 ms, 15.7 ms]) and 8.1 ms (95% CI: [9.4 ms, 10.7 ms]) above baseline 
 
Figure 3-7. APD change in response to two sequential insults of anoxia. 
Vertical gray bars show the two periods of anoxia. Upper Panel: The solid 
blue and red colored lines depict mean APD for control (N = 8) and 
supplemented (N = 8) hearts, respectively. The dot-dash colored lines 
represent individual APD time series for each replicate. For the purpose of 
graphical presentation, each original time series was adjusted to the overall 
pre-anoxia mean. Lower Panel: Estimated difference in mean APD for 




for control and supplemented media groups, respectively. The subsequent APD 
shortening is 39% (59.3 ms, 95% CI: [51.0 ms, 67.7 ms]) for control and 26% 
(40.5 ms, 95% CI: [32.4 ms, 48.6 ms]) for experimental groups. In the course of 
the second anoxia, the first phase transient APD elongation peaks at 1.3 minutes 
(95% CI: [1.0 min, 1.7 min]), which is about 0.9 minutes (95% CI: [0.5 min, 1.3 
min]) faster than in the first anoxia. The magnitude (relative to mean APD just 
before the start of anoxia) is 5.1 ms (95% CI: [-0.4 ms, 10.8 ms]) and 7.4 ms 
(95% CI: [-2.0 ms, 16.7 ms]) for supplemented and normal hearts, respectively. 
The following APD shortening is 48% (73.7 ms, 95% CI:[59.0 ms, 88.4 ms]) in 
the hearts perfused with regular solution and 32.0% (100.8 ms, 95% CI:[86.2 ms, 
115.2 ms]) in the hearts supplied with amino acids.  
Thus the control group shows a significantly larger drop in APD than the 
supplemented group. The difference in dynamics of APD change in response to 
amino acid administration can be easily detected from the estimated difference in 
mean APD for enriched versus normally perfused hearts, as illustrated in the 
lower panel of Figure 3-7. It should be noted that anoxia induces gradual APD 
depression over the entire experiment. The rate of APD decay over the course of 
the experiments in the amino acid supplemented hearts (0.010 ms/s/s, 95% 
CI:[0.005, 0.015]) was less than in control (0.020 ms/s/s, 95% CI:[0.015, 0.025]). 
Notably, there was no evidence of significant decay in APD among hearts 
exposed to a single anoxia event (0.003 ms/s/s, 95% CI:[0.003, 0.009]). On 
average, the APDs for control hearts were 10.8% shorter (13.6 ms, 95% CI: [4.1 
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ms, 23.1 ms]) than hearts supplemented with glutamine and glutamate at the end 




This study investigated the effects of anoxia on cardiac action potential 
duration in the presence or absence of therapeutic doses of amino acids. 
According to the NIH, normal levels of glutamine and glutamate are 
approximately 390-650 μM and 18-98 μM for adults in the fasted state.75 Hearts 
were perfused with glutamine (2500 µM) and glutamate (150 µM) at levels 
somewhat higher than those found in the body naturally. Glutamate was included 
in the media to reduce washout of the cellular stores, since ischemia and anoxia 
lead to ATP depletion and decreased function of the active transporters that 
maintain the high intracellular glutamate gradient.76-78 
Glutamate is found at high tissue/plasma ratios in the heart and is 
associated with increased contractile strength, NADH/NAD+ ratios and ATP 
levels when given to hearts before an anoxic event.78 Glutamine supplementation 
has also been shown to improve contractile function and Ca2+ homeostasis 
during chemical hypoxia.77, 79 Increased intracellular glutamate stores are 
correlated with improved metabolic recovery, increased cardiac output and 
elevated glutathione levels after an ischemic episode.71-73 That said, glutamate is 
a potent neurotransmitter and elevated levels of circulating glutamate have been 
associated with neurological side effects.72, 80  
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Glutamine, on the other hand, has no known toxicity threshold and is 
normally the amino acid of highest concentration in circulation.74 A single dose of 
oral or intravenous glutamine has been shown to improve tissue glutamate levels 
without the need for high levels of glutamate in the plasma.81, 82 This is due to the 
presence of high-affinity transporters for glutamine in the heart, and a high level 
of glutaminase activity, allowing the heart to rapidly convert circulating glutamine 
into intracellular glutamate stores.78 Improved cardiac performance has been 
found with circulating glutamine levels as low as 1.25 mM, a level easily achieved 
by an oral dose of glutamine.72, 73 This has important clinical applications if it can 
be shown that glutamine improves disease outcomes, since there would be a 
wide therapeutic range and negligible risks associated with its use. The 
administration of these amino acids did not appear to alter the hearts normal 
APD since we did not observe any significant difference between control and 
supplemented hearts during the baseline period.  
 
Anoxia 
An interesting behavior occurs at the onset of anoxia: a rapid and 
significant increase in APD. This is of particular interest due to the greater energy 
demands associated with longer APD in the face of decreased metabolic 
capacity from the loss of oxidative phosphorylation. Such behavior was observed 
in 18 of 21 investigated hearts within 3 minutes of anoxia and was independent 
of amino acid supplementation. This phenomenon of initial prolongation of APD 
after metabolic inhibition has been described previously by Carmeliet and 
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Boulpaep in the frog heart83 and later in sheep Purkinje fibers84. Isenberg et al.85 
suggested that initial prolongation of APD in guinea-pig ventricular myocytes 
results from block of the electrogenic Na pump due to ATP depletion. The 
biphasic response in rabbit and human cardiomyocytes to hypoxia and metabolic 
inhibition has been reported by Verkerk et al.86 They detected this phenomenon 
in all subepicardial myocytes, but not in most subendocardial myocytes. They 
found that a decrease in Ito, which occurs prior to the opening of KATP channels, 
underlies the metabolic-induced initial increase in APD.  
Reoxygenation of the heart results in a rapid increase in APD. In both 
groups there was a gradual decline after approximately 8 minutes of 
reoxygenation after both anoxic episodes. It was originally thought that the 
decline in APD seen after the second anoxia was simply a continuation of the 
APD decline caused by the first anoxia and that a single anoxia may result in a 
steady decline in APD regardless of subsequent anoxia. We showed that this 
was not the case by exposing hearts to a single anoxia and monitoring their 
behavior for the same length of time. These data showed that the challenged 
hearts reached a new, albeit lower, steady state 20 minutes post-anoxia and 
remained relatively constant for another 30 minutes. For this reason we chose to 
challenge the hearts multiple times to enhance the effects of the insult and to 
simulate a condition like CHF, where the anoxia may be transitory but repetitive 
in nature. 
Repeating the anoxia also allowed us to explore the effects of cardiac 
preconditioning, a mechanism by which a challenged heart can adapt to the 
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insult and respond more effectively to subsequent insults. In our work the 
application of amino acids significantly decreased anoxia-induced APD 
shortening by 29.9% (18.9 ms, 95% CI:[2.6 ms, 35.1 ms]) in the first anoxia and 
by 36.6% (27.1 ms, 95% CI:[7.7ms, 46.6 ms]) in the second period of anoxia. In 
addition, the amino acids significantly reduced slow APD decay. Since our insults 
were only 20 minutes apart, the heart did not have adequate time to significantly 
change its transcription or translation profiles, so we were looking only at acute 
changes in substrate handling. Thus, the changes we saw are most likely due to 
metabolic effects of the intervention or responses from endogenous proteins. 
Due to the extremely high turnover in the ATP pool from oxidative 
phosphorylation, phosphocreatine cycling and glycolysis, we did not expect to 
see significant ATP/ADP differences between the conditions after the 20-minute 
recovery period. 
While the outermost layer or two of cells may receive oxygen passively 
through contact with the air, this very low level of diffusion is not sufficient to 
supply the heart’s high oxygen demands. Additionally, the MAP probe is in direct 
contact with the epicardium, but the signal it measures is derived from the 
surrounding tissues, possibly reaching as deep as the mid-myocardium. The 
presence of the electrode itself will block diffusion into the underlying tissue from 
the air. The integration of the MAP signal over a depth of underlying tissue 
further minimizes the impact of the few surface cells that receive diffused oxygen. 
Furthermore, we have extensive experience and there is also a large literature on 
the optical measurement of transmembrane potentials in the regionally or 
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globally ischemic heart. We have not seen nor have we found reports of any 
epicardial cardiomyocytes being able to sustain measureable electrical activity 
only through absorption of oxygen from the air. 
 
Statistics  
Our initial strategy was to use Student’s t tests to assess the differences in 
average APD for control versus supplemented hearts following the second 
anoxic episode. However, this approach neglects the variability due to instrument 
calibration, and heart-specific variability in baseline APD. The differences 
observed did not achieve statistical significance using this technique, and 
subsequent numerical investigations revealed that this approach had very little 
statistical power. 
The metabolic and electrophysiological response to ischemia can deviate 
depending on multiple factors, such as vasculature, hormonal status, heart rate 
and metabolic rate, concomitant diseases, gender and age 87-90. The same 
factors could also underlie interspecies variability in the case of anoxia, and 
thereby complicate analysis of the response to anoxia, especially when anoxic 
stress is of short or moderate duration.  
To account for the variability among hearts in the effects of anoxia on APD 
and to properly quantify statistical uncertainty in our work, we utilized nonlinear, 
mixed-effects regression66 to develop a novel statistical method91. By fitting the 
entire time-course of APD measurements to a simple mechanistic model, and 
adjusting for heart-specific baseline variability, we demonstrated a clear and 
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statistically significant difference between the control and supplemented hearts 
(Figure 3-7). Table 3-1 compares the values from the fitted model compared with 
the raw APD measurements at each of the phase transitions.  Related strategies 
are common in the analysis of pharmacokinetics and pharmacodynamics time 
series experiments.92 
 Finally, we relied heavily on 95% confidence intervals to summarize the 
differences between treatment groups. For example, the rate of APD decay in the 
normal media group was 3.2×10-6 ms/s/s faster, relative to the amino acid-
supplemented media group. The 95% confidence interval for this quantity is 
(2.8×10-7, 6.2×10-6). Because this confidence interval does not include zero, 
there is statistically significant evidence that APD decays more slowly in hearts 
perfused with amino acid-supplemented media. This approach to statistical 
significance highlights the estimated magnitude and possible range (with 95% 
confidence) of differences between treatment groups. In particular, this supplants 
the more conventional, but less informative, hypothesis test and p-value 
summary. 
Table 3-1. Comparison of raw data and fitted model values. Values measured 






There are several mechanisms through which these amino acids could 
exert their effects.1 Glutamine and glutamate are interconvertible via a 
transamidation reaction at the cell membrane and within the intracellular space.71 
Glutamate can then be transaminated and enter the TCA cycle as α-
ketoglutarate.70 The ability to produce ATP directly from glutamine and glutamate 
through substrate-level phosphorylation in the TCA cycle can provide a small 
amount of GTP without the need for oxygen (Figure 3-8).30 This could be a crucial 
 
Figure 3-8. TCA Cycle GTP Production. GTP is directly created through 





























reaction that allows the heart to maintain a minimal level of pump and muscle 
function, giving the heart a slightly longer period of resistance to anoxia. When 
we began these experiments we found this theory quite compelling. However, 
only a very small amount of ATP can be produced through this mechanism since 
each molecule of glutamate or glutamine can produce only one GTP and one 
NADH molecule (which cannot be oxidized under anoxic conditions) in their 
conversion to succinate. In contrast, a single molecule of acetyl-CoA produces 
one GTP, 3 NADH and one FADH2, which will yield approximately 10 ATP 
through oxidative phosphorylation. Also, the reducing environment of the 
ischemic heart inhibits these reactions, as does the accumulation of NADH. 
Since NADH requires oxygen for deprotonation, this can become a limiting 
reagent of the α-ketoglutarate to succinyl-CoA reaction before substrate-level 
phosphorylation can occur. We have shown that the control and supplemented 
hearts have no significant APD differences during the anoxic episodes and that 
the differences between the conditions emerge only after several minutes of 
reperfusion. This strongly suggests that the cardioprotective effects occur only 
after oxygen supply returns. Hence, we no longer believe that ATP production 
during anoxic challenge is the primary mechanism responsible for the 
cardioprotective effects of glutamine and glutamate. 
Another possible method of glutamine-mediated metabolic support is 
anaplerosis, or replacement of depleted intermediates. As stated above, 
glutamine and glutamate readily enter the TCA cycle. This additional supply of 
TCA cycle intermediates could support the return of oxidative phosphorylation 
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during reperfusion by maintaining the levels of TCA cycle intermediates during 
ischemia and early reperfusion. Since ischemia normally results in losses of 
membrane integrity and ion compartmentalization, this reinforcement could be 
essential to return the heart to normal function. This mechanism is supported by 
the data in that the differences between the conditions emerge only during the 
late reoxygenation periods when oxidative phosphorylation should be recovered 
and meeting the needs of the struggling heart.  
A third explanation is that glutamate and, by extension, glutamine may 
reduce the effects of reactive oxygen damage through their conversion to the 
potent antioxidant, glutathione (Figure 3-9). Glutathione can be produced from 
amino acid precursors and is an effective antioxidant within the cell. It is possible 
that glutamine and glutamate contribute to cellular stores of glutathione, reducing 
the damage from reactive oxygen species (ROS). This is an ATP-dependent 
reaction that would necessarily take place before the onset of anoxia to 
effectively reduce ROS damage during anoxia. It also requires other amino acids 
to assemble the final glutathione molecule. For these reasons we do not believe 
 
Figure 3-9. Mechanism of glutathione production from amino acid precursors. 
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Glutamate + Cysteine Glutamylcysteine + Glyceine Glutathione
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that this is the mechanism responsible for the APD enhancement we see in these 
experiments. That said, this pathway may play a role in long-term recovery from 
anoxic insults and may be another compensatory mechanism that would prepare 






CARDIAC ISHEMIA AND AMINO ACIDS 
 
Introduction 
Cardiac ischemia is the leading cause of death and is responsible for the 
majority of hospital admissions in the United States.93 These acute ischemic 
events are usually caused by asymptomatic atherosclerosis that reduces blood 
flow to the tissues and leaves the heart vulnerable to oxygen deprivation during 
exercise or elevated cardiac output. Due to the often subtle and transient nature 
of these episodes, cardiac ischemia is often undetected until it causes a fatal 
heart attack. In light of this, it is important to study cardiac ischemia as a 
“chronically acute” event in which the heart is repeatedly subjected to short, non-
lethal ischemic episodes, much as it would happen in vivo.  
The heart’s ability to alter its metabolism and overall behavior to reduce 
the threat from ischemia means that its ischemic response will change over time, 
as will its post-ischemic recovery.94, 95 Ischemic preconditioning is a well-known 
phenomenon in cardiology that is often overlooked in basic research settings of 
single-ischemia challenges.30 We established in the previous chapter that the 
heart alters its electrophysiology in response to sequential anoxia challenges, 
and we now explore both the electrophysiology of ischemia and what happens to 
the heart over longer time scales. If the heart exhibits significant metabolic 
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changes after only two anoxic challenges over 52 minutes, then we expect to see 
even greater changes after three ischemic challenges over 90 minutes. 
The principal reason for our use of ischemic challenge rather than more 
anoxic challenges is clinical relevance – far more patients suffer infarctions and 
atherosclerosis than drowning, carbon monoxide poisoning or pulmonary edema. 
A secondary consideration was that the original thesis proposal contained 
perfusate sampling techniques that were not possible during stopped-flow 
conditions and required constant flow. This necessitated anoxic challenges due 
to the ability to maintain perfusion. These methods were not used in our 
experiments, so there was no longer any concern about flow rates. 
The importance of amino acids, however, remains highly relevant in the 
context of ischemia since the lack of oxygen still inhibits the normal functions of 
the heart.28, 41 We continued to use the same media and the same amino acid 
levels as in the previous experiments to compare the responses in the anoxic 
and ischemic hearts. The glutamine and glutamate were expected to exert similar 
effects since the same pathways are expected to have similar dynamics in both 
conditions. 
We expanded our action potential duration (APD) measurements from 
APD90 only to include dV/dtmax, APD50 and APD70 as well as APD90. This allows 
us to more thoroughly explore the behavior of the heart and determine exactly 
how the heart’s action potential (AP) is responding to the ischemia and the amino 
acids. Using these three additional parameters we are able to plot the shape of 
the AP to see how long the heart is maintaining calcium currents and other ion 
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channels. These parameters will help us link the metabolism and 
electrophysiology to calcium signaling and mechanical function. The AP shape 
will also help us determine the mechanism of amino acid-mediated 
cardioprotection. 
To test the effect of amino acid anaplerosis of the TCA cycle, we 
introduced a new compound to our experiments: aminooxyacetate (AOA). This 
molecule is an amino acid transaminase inhibitor that has been shown to block 
the action of the glutamate transaminase that converts glutamate to α-
ketoglutarate.30 Since we proposed that this was the primary mechanism for the 
cardioprotective effects of these amino acids, this compound was expected to 
negate the APD increases in the supplemented group. 
In the course of these experiments we found that the amino acid-enriched 
group did in fact have significantly higher APDs than the control group and that 
the AOA completely blocks this increase when given in conjunction with the 
amino acids. The effects are most prominent in the APD50 group, indicating that 
the amino acids exert significant effects on maintaining a longer, more normal AP 
than the control group. This has important implications in the clinical setting as it 
indicates that glutamine supplementation may significantly improve the most 
fundamental level of cardiac function: the action potential.  
 
Results 
A total of 31 hearts (8 AA-/AOA-, 8 AA+/AOA-, 8 AA-/AOA+, 7 AA+/AOA+) 
were perfused, paced and monitored over a period of 110 minutes (see Figure 2-
5). This included 20 minutes to establish baseline APD and three 10-minute 
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episodes of ischemia with 20 minutes of recovery each. After the experiments the 
hearts were frozen at -80°C and later analyzed for isoprostanes, isofurans and 
tissue amino acid levels. 
 
Action Potential Duration  
APD was measured at three points along the AP curve: 50% of maximum 
AP amplitude (APD50), 30% of maximum AP amplitude (APD70) and 10% of 
maximum AP amplitude (APD90). The data were used to construct a fitted model 
of APD behavior at each point over time with a 95% confidence interval (CI). The 
value and CI at the end of each stage of the experiment are shown in Table 4-1.   
 
APD50 
AA-/AOA- hearts had a baseline APD50 of 96 ms (95% CI: [82 ms, 109 
ms]) (Figure 4-1A). Each reperfusion period resulted in a small but significant 
increase in APD50 compared to baseline. The final APD50 was 113 ms (95% CI: 
[93 ms, 134 ms]). 
AA+/AOA- hearts had a baseline APD50 of 119 ms (95% CI: [88 ms, 146 
ms]) (Figure 4-1B). Each reperfusion period resulted in increasingly higher APD50 
compared to baseline. The final APD50 was 164 ms (95% CI: [138 ms, 197 ms]). 
AA-/AOA+ hearts had a baseline APD50 of 143 ms (95% CI: [112 ms, 173 







































































































114 ms (95% CI: [87 ms, 139 ms]) (Figure 4-1D). Neither of these groups 
showed a significant change in APD50 at the end of the experiment. 
 
APD70 
AA-/AOA- hearts had a baseline APD70 of 115 ms (95% CI: [101 ms, 129 
ms]) (Figure 4-2A). Each reperfusion period resulted in a small but significant 
increase in APD70 compared to baseline. The final APD70 was 148 ms (95% CI: 
[127 ms, 168 ms]). 
Figure 4-1. Model-fitted mean for APD50 (in ms) for each experimental 
condition. Gray bars show ischemic periods, the mean is shown in solid black, 
95% CI is shown in dashed black, and raw data are shown in dashed gray 
lines. Of the four conditions, only the AA+/AOA- group exhibits a significantly 




AA+/AOA- hearts had a baseline APD70 of 136 ms (95% CI: [103 ms, 168 
ms]) (Figure 4-2B). Each reperfusion period resulted in increasingly higher APD70 
compared to baseline. The final APD70 was 180 ms (95% CI: [151 ms, 217 ms]). 
AA-/AOA+ hearts had a baseline APD70 of 161 ms (95% CI: [139 ms, 185 
ms]) (Figure 4-2C). The AA+/AOA+ group had a baseline APD70 of 140 ms (95% 
CI: [111 ms, 167 ms]) (Figure 4-2D). Neither of these groups showed a 
significant change in APD70 at the end of the experiment. 
 
Figure 4-2. Model-fitted mean for APD
70
 (in ms) for each experimental 
condition. Gray bars show ischemic periods. Model-fitted mean is shown in 
solid black, 95% CI in dashed black, and raw data in dashed gray lines. The 
control group (AA-, AOA-) also exhibits slightly elevated APD at the end of the 





AA-/AOA- hearts had a baseline APD90 of 143 ms (95% CI: [131 ms, 158 
ms]) (Figure 4-3A). Each reperfusion period resulted in a small but significant 
increase in APD90 compared to baseline. The final APD90 was 175 ms (95% CI: 
[146 ms, 197 ms]). 
Figure 4-3. Model-fitted mean for APD90 (in ms) for each experimental 
condition. Gray bars show ischemic periods. Model-fitted mean is shown in 
solid black, 95% CI in dashed black, and raw data in dashed gray lines. APD90 
results demonstrate a significant shortcoming as a measurement point, as the 
weak AP during ischemia can exhibit a long APD due to the sharp shape of 
the restitution curve and slow recovery to resting membrane potential. During 
the recovery periods, however, the AP shape recovers and shows that the 





AA+/AOA- hearts had a baseline APD90 of 172 ms (95% CI: [146 ms, 196 
ms]) (Figure 4-3B). Each reperfusion period resulted in increasingly higher APD90 
compared to baseline. The final APD90 was 223 ms (95% CI: [188 ms, 263 ms]). 
AA-/AOA+ hearts had a baseline APD90 of 190 ms (95% CI: [166 ms, 215 
ms]) (Figure 4-3C). The AA+/AOA+ group had a baseline APD90 of 168 ms (95% 
CI: [143 ms, 193 ms]) (Figure 4-3D). Neither of these groups showed a 
significant change in APD90 at the end of the experiment. 
 
APD Differences  
 We determined the difference between conditions by finding the difference 
between the fitted models and calculating a 95% CI for each comparison. The 
conditions were considered significant if the CI did not include zero. The 
difference between each condition at each stage of the experiment is shown in 
Table 4-2. 
 
AA-/AOA- vs. AA+/AOA- 
 AA+/AOA- and AA-/AOA- hearts showed no significant difference in APD 
during the baseline period or first reperfusion. Over the course of the second 
reperfusion the AA+/AOA- hearts began to show significantly higher APD50 and 
APD90 than the AA-/AOA- hearts. By the end of the third reperfusion the 
AA+/AOA- hearts had significantly higher APD50, APD70 and APD90 than AA-



































































































 AA+/AOA- vs. AA+/AOA+ 
 AA+/AOA- and AA+/AOA+ hearts showed virtually no difference in APD 
during the baseline period. There were no significant differences in APD 
throughout the first and second reperfusion periods, but by the end of the third 
reperfusion the AA+/AOA- hearts had significantly higher APD50, while APD70 
and APD90 were not significantly higher compared to the AA+/AOA+ hearts 
(Figure 4-5). 
 
Figure 4-4. Difference between AA-/AOA- and AA+/AOA- hearts. A) APD50, B) 
APD70, C) APD90. Amino acid supplementation significantly increases APD 





 AA-/AOA- vs. AA-/AOA+ 
 The AA-/AOA+ group had a significantly higher baseline APD than the AA-
/AOA- group. This difference diminished over the course of the experiment, as 
the control group’s APD increased in response to the ischemia and reperfusion 
 
Figure 4-5. Difference between AA+/AOA- and AA+/AOA+ hearts. A) APD50, 
B) APD70, C) APD90. Addition of the transaminase inhibitor AOA inhibits the 
effects of AA supplementation, as the AA+/AOA- group has significantly longer 
APD than the AA+/AOA+ group. 
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while the AA-/AOA+ did not. By the end of the experiment there was no 
significant difference between the two conditions at APD50, APD70 or APD90 
(Figure 4-6). 
 
 AA-/AOA+ vs. AA+/AOA- 
 There was no significant difference between the AA-/AOA+ and 
AA+/AOA+ groups at any time for APD50, APD70 or APD90 (Figure 4-7). 
 
Figure 4-6. Difference between AA-/AOA- and AA-/AOA+. A) APD50, B) APD70, 
C) APD90. Addition of AOA decreases AP in the normal heart, but by the end of 




Action Potential Slope 
Action potential duration was measured at three points along the action 
potential curve: APD50, APD70 and APD90. These points measured jointly 
illustrate the shape of the action potential and can discriminate between strong 
and weak action potentials more accurately than a single point measurement 
(Figure 4-8). In this figure, a strong AP is shown in red with the characteristic 
“plateau and shoulder” followed by a rapid return to baseline. A weak AP, on the 
 
Figure 4-7. Difference between AA-/AOA+ and AA+/AOA+ hearts. A) APD50, 
B) APD70, C) APD90. AOA negates the effects of amino acid supplementation 
as the AA+/AOA+ and AA-/AOA+ groups show no significant differences 
throughout the recovery periods. 
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other hand, will have little or no plateau and may have a fast or slow return to 
baseline. If a weak AP has a slow return to baseline, then a single APD90 
measurement may not be able to distinguish between a strong or weak AP. 
However, if multiple points are measured on the curve then it becomes much 
easier to distinguish strong and weak APs. 
We plotted the AP repolarization slope at the end of each recovery by 
applying a linear best fit through APD50, APD70 and APD90 (Figure 4-9). A higher 
slope equates to faster membrane repolarization through robust ion transporter 
function, indicating healthy cellular function. The slopes for all groups experience 
 
Figure 4-8. Comparison of strong and weak action potentials. Strong action 
potentials are characterized by a sustained membrane potential “plateau” 
around 90% of the maximum action potential, followed by a rapid 
repolarization. Weak action potentials exhibit little to no plateau and a 




recovery decay over the course of the experiments but the enriched (AA+/AOA-) 
group appears to show less recovery decay than the other groups.  
By normalizing the data to highlight the change in AP slope over the 
course of the experiment we could more easily visualize the trends in AP slope at 
the end of each reperfusion stage (Figure 4-10). There is a steady trend in all of 
the data toward a less negative slope, but the enriched group shows markedly 
 
Figure 4-9. Slopes of the AP repolarization at the end of each recovery period. 
Over the course of the experiment there is a gradual decrease in the rate of 
repolarization for all hearts, but the AA+/AOA- group has a slower rate of 
repolarization decay than the other groups. Repolarization slope was defined 




less decay than the other groups (.08 vs .16 % recovery/ms). The significance of 
these values has not yet been evaluated. 
 
Isoprostanes and Isofurans 
 Frozen samples of the ventricular wall were sent to Jackson Roberts’s lab 
in two batches. The initial results indicated that the amino acid-enriched group 
 
Figure 4-10. Baseline-adjusted AP repolarization slopes at the end of each 
recovery period. Repolarization slopes were recalculated by finding the 
change in the repolarization rate from the baseline period. Using this analysis, 
we found that the amino acid enriched group (AA+/AOA-) decayed 50% 
slower than the next closest group (AA-/AOA+) (.08 vs. .16 % recovery/ms). 
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may have lower isoprostane and isofuran levels than the other groups, but the 
results were not significant (p=.09) (Figure 4-11).  
To increase the power of the study we analyzed additional hearts. 
Unfortunately, these were slightly smaller tissue samples and, according to the 
Roberts lab, smaller samples will have higher levels of auto-oxidation during the 
preparation, resulting in higher levels of isoprostanes and isofurans. We 
discovered this phenomenon once we plotted the sample mass in relation to the 
 
Figure 4-11. Initial results from the isoprostane analysis. This initial group of 
samples was small but exhibited tantalizing suggestions of cohort groupings 































































































isoprostane levels (Figure 4-12). The smaller samples have significantly higher 
isoprostane and isofuran levels regardless of the experimental conditions. This 
introduced huge variability into the dataset and we could therefore draw no 




Figure 4-12. Complete isoprostane dataset. Enlarging the number of samples 
in the analysis eliminated any suggestion of experimental differences, 
revealing instead a relationship between the sample mass and the 
isoprostane and isofuran content. It is unclear how these are related, but the 


































































































Overall the data support the hypothesis that glutamine and glutamate 
supplementation increases APD, especially APD50, and that this effect is 
mediated at least partially through the transamination of the amino acids. Based 
on the model-fitted data, APD50 increased by 38% in the AA+/AOA- compared to 
18% in the AA-/AOA- and less than 1% in both the AA-/AOA+ and AA+/AOA+ 
groups over the course of the experiment. APD70 showed a less significant 
increase of 33% in the AA+/AOA- group, 28% increase in the AA-/AOA- and 5% 
decreases in the AA-/AOA+ and AA+/AOA+ groups. APD90 also showed a 
significant increase of 29% in the AA+/AOA- group compared to the 22% 
increase in the AA-/AOA- group, 10% increase in the AA+/AOA+ group and 2% 
increase in the AA-/AOA+ and group. 
In the context of APD it is important to note that the shape of the AP is 
equally significant as (if not more significant than) a single duration 
measurement. For this reason it is of special note that the AA+/AOA- group 
appears to have a steeper AP return stroke than the other groups (though 
additional statistics will be required to verify this). This is a highly encouraging 
finding when coupled with the longer APD of the AA+/AOA- group as it indicates 
that the plateau and shoulder phase of the AP are longer in this group and that 
the cardiomyocytes are repolarizing more quickly. Since the plateau of the AP is 
associated with calcium signaling we can reasonably expect the enriched group 
to have greater contractile function than the other groups. 
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Since the AOA treatment results in a significant increase in baseline APD 
compared to the AA-/AOA- group, there is apparently an amino acid-independent 
effect of this treatment. This is likely due to inhibition of the malate-aspartate 
transaminase, though how this would lead to increased baseline APD is unclear. 
Further studies will be necessary to elucidate this link. 
Based on this study alone we can reasonably conclude that glutamine and 
glutamate supplementation may significantly improve the electrical function of the 
heart in the context of acute and “chronically acute” myocardial ischemia and that 
further studies are warranted. It may be that prophylactic doses of amino acids 
will become de rigueur for those at risk of an ischemic event along with current 






SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
In this work we investigated, for the first time to our knowledge, the effect 
of amino acid administration on the electrical properties of the heart during 
sequential transitional periods of anoxic and ischemic challenge. Because of the 
variability among hearts in baseline APD, and in their response to anoxic events, 
conventional statistical analysis (e.g., using a series of two-sample t-tests) was 
not appropriate. We accounted for this variability by fitting a simple mechanistic 
model using nonlinear mixed-effects regression.91 Thus we could clearly 
distinguish the effect of amino acid supplementation on mean APD dynamics in 
response to these challenges. Our findings provide valuable insights into the 
interplay of metabolism and electrophysiology by showing that mitigation of 
energy deficits has immediate effects on electrical function, which may improve 
survival rates during anoxic or ischemic events. These results are significant and 
conserved across both anoxia and ischemia, indicating that this is a reliable and 
effective intervention for extending APD and possibly improving cardiac function. 
The results indicate that a significant portion of the cardioprotective effect 
is exerted through the transamination of glutamate and glutamine into α-
ketoglutarate since blockage of transamination blocked the effect of amino acid 
supplementation. This is not to say that glutathione production is not also a factor 
90 
 
in the cardioprotective effect. The reduction in ROS may be significant for long-
term recovery and ischemic pre-conditioning, but this did not have a significant 
effect over the course of our experiments.Our model system was the Langendorff 
perfused heart system, which is a valuable experimental approach that allows a 
vast amount of flexibility in measurements and interventions but with one 
significant difference from an in vivo heart: it is not a “working heart”. A working 
heart model has either an intraventricular balloon or an aortic hydrodynamic load 
that provides resistance to the contraction of the ventricle to more accurately 
model the behavior of the intact organ.96, 97 The increased workload on the heart 
would increase the energetic demands of the heart and also allow measurement 
of cardiac mechanical function in addition to action potentials. We did perform a 
few early experiments with the contraction blocker blebbistatin but this complete 
elimination of contractile work made the hearts extremely resistant to ischemic 
and hypoxic APD shortening. These results indicate that the ATP consumption 
through mechanical function is a significant portion of the total metabolic load of 
the heart which is suported by the literature.98 However, we felt that the 
increased complexity of the system would not be justified for a minimal increase 
in clinical significance of what we viewed as a pilot study. This may be a valuable 
component to add in the future to investigate the increase in energy demand and 
degree of challenge from an ischemic episode. 
We are eager to see these studies extended to the clinical setting as the 
intervention they indicate has immediate applicability and is an immediate 
necessity. With heart disease and other metabolic disorders on the rise, we can 
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Although these studies have revealed many heretofore unknown 
behaviors, they have also suggested additional lines of questioning. We have 
established the significance of metabolism in the development of APD and the 
effect of amino acid supplementation, but it is apparent that we need to quantify 
the TCA cycle intermediates. This will conclusively establish the degree to which 
amino acids affect the TCA cycle and the energetic state of the cells. 
It is not entirely clear how AOA interacts with the cell as a whole, since we 
found a significant increase in baseline APD in AA-/AOA+ hearts compared to 
AA-/AOA-. Further replicates may reveal that our sample size was not large 
enough or that the AOA does in fact have some heretofore unknown effect on the 
AP. 
These experiments also revealed an interesting feature in the shape of the 
AP itself. The initial ischemic and anoxic responses both produced a significant 
transient increase in APD of approximately 10-20 ms that lasted for one to two 
minutes. This was followed by a larger APD reduction of up to 50 ms that lasted 
for the remainder of the ischemic or anoxic episode. These initial increases 
occured rapidly in the first challenge, and slightly slower and with a shorter 
duration and amplitude in subsequent challenges. It is as yet unknown what 
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gives rise to this feature but this may be a response to a novel insult that is 
reduced or mitigated after the first exposure.  
We must also begin using our dual-camera imaging system to measure 
other important intermediates, especially calcium and NADH. These 
investigations were not included in these studies due to the additional 
instrumentation and, in the case of calcium imaging, additional dyes. Now that 
the experimental protocol is fully developed and the other detection methods are 
fully operational, it is appropriate to consider these imaging modalities. They will 
allow us to quantify the specific energetic and contractile intermediates 
responsible for the action potential with negligible difficulty. 
There were apparent differences in APD during the anoxic and ischemic 
periods but the high variability in the data requires additional analysis and 
experimentation to determine the significance in these differences. The recovery 
periods exhibited clear and significant differences in the amino-acid-enriched 
groups in the absence of AOA. We hypothesize that the maintenance of the 
metabolic machinery via anaplerosis was responsible for the rapid recovery of 
these groups and the sustained improvements over subsequent challenges.  
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To identify the contributions of the TCA cycle products, we could expose 
the heart to ischemia and hypoxia in the presence of the electron transport 
inhibitors listed in Table 5-1. These interventions would fully test the aerobic 
respiratory pathway to determine at what step of the TCA cycle, shown in Fig.1-
2, the amino acids exert their effects. Both glutamine and glutamate enter the 
TCA cycle as α-ketoglutarate. From this point they continue through the cycle to  
produce NADH, GTP and FADH2. These high-energy metabolites are then used 
to power proton pumps in the inner mitochondrial membrane through a series of 
enzymes that gradually release the energy stored in the NADH and FADH2. By 
selectively inhibiting the activity of these intermediate electron transport 
complexes, we can determine which high-energy metabolites are most essential 
for the cardioprotective effects of these amino acids. 
Table 5-1. List of electron transport inhibitors and their mechanisms of action. 
Chemical 
Agonist 
Mode of Action Result Expected Degree of Survival 
Rotenone Blocks complex I NADH Blocked 
High – FADH2 oxidation still 
produces significant levels of ATP 
Antimycin Blocks complex III 
NADH/FADH2 
Blocked Early 
Low – Early transport blockage, 
minimal ATP produced 
Carbon 
monoxide 
Blocks complex IV 
NADH/FADH2 
Blocked Late 
Moderate – Late transport 
blockage, significant ATP 
produced 
Anoxia Blocks complex IV 
NADH/FADH2 
Blocked Late 
Moderate – Late transport 
blockage, significant ATP 
produced 
Oligomycin 




but no ATP 
produced 
Very Low – Free radical 




Rotenone specifically inhibits complex I of the ETC, the complex 
responsible for removing the electrons from NADH (Fig. 5-1). It does not, 
however, affect the oxidation of FADH2 as this enters the cycle in complex III via 
complex II, which converts succinyl-CoA to fumarate to produce the FADH2. We 
would predict that rotenone would increase the uptake of glutamate and 
glutamine, as they will still be able to provide electron donors through this 
mechanism, thereby maintaining the proton gradient and ATP production. It may 
also lead to release of aspartate and asparagine through cataplerosis, as they 
 
Figure 5-1. Electron transport chain (ETC) and oxidative phosphorylation. 
NADH and FADH2 are produced through metabolism of TCA cycle 
intermediates. They are oxidized by complexes I and II, respectively, to 
generate the proton gradient across the inner mitochondrial membrane. The 
elevated proton concentration in the inter-membrane space is then coupled to 
ATP generation by ATP synthase. The final electron acceptor in the electron 
transport chain is oxygen. A lack of oxygen or inhibition of any of the ETC 






















Rotenone – Inhibits complex I
Antimycin A – Inhibits complex III
Anoxia, CO2 – Inhibits complex IV
Oligomycin – Inhibits ATP Synthase
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are possible products of an abundance of oxaloacetate. Since rotenone does not 
completely block electron transport, we would expect this to have only minor 
effects on APD since oxidative phosphorylation could still occur. 
Blockage of complex III will likely be much more damaging than complex I 
blockage, since this stops both NADH and FADH2 oxidation. Even complex IV 
inhibition still allows partial energy capture through the early steps of electron 
transport, and partial maintenance of proton flux. All of these inhibitors will likely 
dramatically reduce glutamine and glutamate uptake, as well as alanine release 
and cell survival. APD depression and arrhythmias would be expected to occur in 
most cases. 
We would predict oligomycin to be the most damaging of the ETC 
inhibitors, as it blocks the activity of the ATPase responsible for harnessing the 
energy of the proton gradient. Its inhibition would allow the cell to burn 
metabolites and produce acidic by-products, and yet produce no energy. This 
intervention is expected to have a very low survival and very little metabolic 
activity after even short exposures. 
To determine the effect of glutathione production on amino-acid-induced 
cardioprotection we could use buthionine sulfoximine (BSO) to selectively inhibit 
gamma-glutamylcysteine synthetase, an essential enzyme for the synthesis of 
glutathione. Blockage of this enzyme would eliminate this pathway as a possible 
mechanism for cardioprotection in the heart. 
The glutamine used in these studies is the same L-glutamine found in high 
levels in many Asian diets. It may be that people with higher dietary glutamine 
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intake have higher levels of plasma glutamine, but we have not investigated this. 
According to our findings, if there are higher levels of glutamine in the blood there 
may be an increase in hypoxia resistance. This might make an interesting case 
study: dietary glutamine intake and anoxia tolerances of indigenous Everest 
sherpas vs. Western climbers. However, this type of study is obviously beyond 
the purview of our lab. 
We would also need to include a down-stream analysis of cardiac effluent 
and post-ischemic tissues to determine the metabolic flux of the heart. By using 
an approach like UPLC-IM-MS we could very accurately measure the molecular 
composition of the proteome and metabotolome and clearly identify the pathways 
through which these amino acids exert their effects. Coupling this with 
microdialysis techniques we could also measure the uptake and release of key 
molecules within the interstitium of the myocardium over the course of the 
experiment. This approach would allow us to measure metabolites immediately 
around the cells before these metabolites enter the circulatory system, thereby 
eliminating the problems of time delay and dilution inherent in the sampling of 
whole heart effluent, as the metabolites do not travel through the blood vessels 
or across the endothelium before being detected. 
It would also be valuable to quantify the activity of hypoxia-inducible factor 
(HIF) in ischemic and anoxic hearts. HIF is a heterodimeric protein with a 
constitutively-expressed β-subunit and an α-subunit that is readily ubiquitinated 
and degraded by prolyl hydroxylases in the presence of oxygen and α-
ketoglutarate.99-101 In the absence of oxygen, the dimers bind and activate a 
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significant portion of the transcriptome associated with angiogenesis, anti-oxidant 
production, enhanced glycolysis and reduced inflammation. While this pathway is 
not likely to significantly alter the outcomes of acute ischemic and anoxic 
challenges over the course of our experiments, it will likely have a major impact 
on longer term processes that would be involved in ischemic pre-conditioning in 
clinical settings. Hence affinity assays or targeted mass spectrometry might 
detect a transient increase in HIF-1α following each of the ischemic/anoxic 
challenges, and analysis of the transcriptome might reveal changes in gene 
transcription associated with modulation of HIF by hypoxia.99, 100 
The over-arching goal of our research has been to unite the disparate 
fields of electrophysiology and cardiac metabolism. Existing models of cardiac 
electrophysiology have focused exclusively on ion flux, channels, and potentials 
and as a result there is very little metabolic regulation within the models.102-107 
More recent advances in the models have used TCA cycle “energy output” as a 
metabolic input,108, 109 but this neglects the rich metabolic network responsible for 
the various forms of energy sources including NADH, FADH2, ATP, creatine 
phosphate and even energy stores like glucose and fatty acids. Given the 
complex signaling and metabolic networks that regulate the heart, it would be 
ideal were the models to have metabolic demand, e.g., exercise, and nutrients as 
the inputs to the model, such that one could observe how changes in either 
demand or nutrients affected cardiac metabolism and electrophysiology. By 
coupling electrophysiological outputs like APD and AP propagation to metabolic 
perturbations we hope to better bridge this gap and encourage more discussions 
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between these “disparate” fields. Metabolic flux analysis or other approaches 
would allow the cardiac modeling community to begin incorporating these 
metabolites and processes using real data with measurable changes over time, 
especially if this analysis included simultaneous measurements of the electrical 
function of the heart. To our knowledge, experiments such as those described in 
this dissertation have not been carried out before and we hope that our pilot 
studies mark the start of a larger trend toward integration of the separate fields of 
cardiac physiology. These steps will, in the future, contribute to the eventual 
integration of all organ systems and models into all-encompassing whole 
organism predictive models capable of predicting disease outcomes and 
treatments in silico. 
Future experiments will clearly be needed to more fully explore the exact 
mechanism of cardioprotection exerted by these amino acids and their effect on 
electrophysiology and clinical outcomes. Should these amino acids prove 
beneficial, we could foresee a time when at-risk patients would be prescribed 
glutamine supplements just like the aspirin regimens we see today. Due to the 
low risk and the low cost of the amino acids themselves, this could have a 
significant impact on morbidity and mortality with very little increase in medical 
costs. 
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SUMMARY. We present an application of mechanistic modeling and nonlinear longitudinal regression in the context of
biomedical response-to-challenge experiments, a ﬁeld where these methods are underutilized. In this type of experiment, a
system is studied by imposing an experimental challenge, and then observing its response. The combination of mechanistic
modeling and nonlinear longitudinal regression has brought new insight, and revealed an unexpected opportunity for optimal
design. Speciﬁcally, the mechanistic aspect of our approach enables the optimal design of experimental challenge characteristics
(e.g., intensity, duration). This article lays some groundwork for this approach. We consider a series of experiments wherein
an isolated rabbit heart is challenged with intermittent anoxia. The heart responds to the challenge onset, and recovers
when the challenge ends. The mean response is modeled by a system of diﬀerential equations that describe a candidate
mechanism for cardiac response to anoxia challenge. The cardiac system behaves more variably when challenged than when
at rest. Hence, observations arising from this experiment exhibit complex heteroscedasticity and sharp changes in central
tendency. We present evidence that an asymptotic statistical inference strategy may fail to adequately account for statistical
uncertainty. Two alternative methods are critiqued qualitatively (i.e., for utility in the current context), and quantitatively
using an innovative Monte-Carlo method. We conclude with a discussion of the exciting opportunities in optimal design of
response-to-challenge experiments.
Key words: Bootstrap; Diﬀerential equation; Longitudinal data; Mechanistic model; Optimal experimental design.
1. Introduction
Observing the time series of response to designed physiological
challenges is a powerful tool for biomedical research and diag-
nostics. The cardiac stress test is a well-known example. There
is an emerging eﬀort to utilize this methodology in studies of
isolated tissues, and even single cells (Wikswo, Lin, and Ab-
bas, 1995; Wikswo et al., 2006; Faley et al., 2008; Eklund et
al., 2009; Enders et al., 2010; Snider et al., 2010; LeDuc, Mess-
ner, and Wikswo, 2011). This response-to-challenge method-
ology is part of a system-level approach (opposite a reduction-
ist approach), and has become more prominent in the study
of complex metabolic, signaling, and gene regulatory path-
ways (Garcia et al., 2011). Mechanistic mathematical mod-
els (e.g., systems of diﬀerential equations) are often used to
characterize the mechanisms that underlie a biological sys-
tem. The system is studied by making empirical observa-
tions on some of its parts, and then drawing inferences about
the unobserved parts. This type of modeling and inference is
common in epidemiology and pharmacology, for example (see
Edelstein-Keshet (2005) for a comprehensive introduction),
but is largely neglected in other basic sciences.
While the experimental response-to-challenge methodology
has advanced, tailored statistical methods have lagged. As a
result, the statistical methods employed often make unrealis-
tic assumptions, fail to account for complexities in the data, or
fail to adequately characterize (or worse, misleadingly char-
acterize) the evidence about important scientiﬁc questions.
Indeed, May (2004) highlights the use of conventional statis-
tical methods and assumptions in highly nonlinear dynamical
processes as an abuse of mathematics in biology. The impetus
for the current work was a concern that important biological
insights might be missed at the time of statistical analysis;
that without suﬃcient care, statistical analysis might hinder
rather than promote scientiﬁc discovery.
The response-to-challenge approach was implemented to
study the connection between cardiac electrophysiology and
metabolism using a series of measurements on isolated rab-
bit hearts. The cardiac tissue was perfused with either normal
media or amino acid enriched media. Cardiac action potential
duration (APD) was measured in a time course of intermit-
tent metabolic challenges. In this experiment, two intermit-
tent challenges were imposed by withholding oxygen from per-
fusion media (anoxia), thereby simulating the eﬀect of acute
lung injury, pulmonary embolism, asphyxia, and other res-
piratory conditions. The primary biological endpoint of the
experiment was to draw inferences about the cardioprotec-
tive eﬀect of amino acid enrichment under intermittent anoxia
challenges.
In separate experiments (data not shown), no cardiopro-
tective eﬀect was evident in the absence of anoxia challenge,
or when only one anoxia challenge was applied. We hypoth-
esized that repeated anoxia would further strain the cardiac
tissue, and be more likely to reveal a cardioprotective eﬀect
for amino acid enrichment.
We employed a mechanistic diﬀerential equation model for
the change in cardiac APD over time, accounting for initiation
and termination of the metabolic challenge events, and to pa-
rameterize the eﬀect of amino acid enrichment. This type of
mechanistic model serves the immediate goal of drawing sta-
tistical inferences about the eﬀect of amino acid enrichment,
© 2013, The International Biometric Society 74199
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but is also useful in making predictions about how cardiac
tissue behaves under anoxic stress. In particular, we are in-
terested in predicting the consequence of modifying the chal-
lenge characteristics (e.g., extending the duration of anoxia)
on the mean APD response. This type of prediction is use-
ful, for example, in the design of new response-to-challenge
experiments.
Complex variability, including residual autocorrelation and
heteroscedasticity, is a prominent feature of the cardiac APD
data. As the evidence presented below suggests, the anoxia
challenge aﬀects both mean and variance of the response. Be-
cause of this complexity and the small-sample nature of these
data, there was concern about the use of asymptotic results
(under strong parametric assumptions) for statistical infer-
ence. Indeed, Sohn and Menke (2002) reported that inference
based on asymptotic results had underestimated uncertainty
in a related nonlinear regression application, and recommend
a bootstrap alternative.
Three distinct estimation and inference strategies were
evaluated in the current context: ordinary least squares (OLS)
estimation with nonparametric bootstrap inference, maxi-
mum likelihood estimation (MLE) with nonparametric boot-
strap inference, and MLE with asymptotic inference. The fre-
quent coverage of pointwise (i.e., points in time) conﬁdence
bands, and the power associated with pointwise hypothesis
tests were examined using a novel Monte-Carlo method. Sur-
prisingly, coverage was similar for the bootstrap OLS and
bootstrap MLE methods. The asymptotic MLE method had
lesser coverage in general, and especially less for time points
within the anoxia challenge periods.
Our objective in studying alternative estimation and in-
ference strategies was to better inform our analysis of the
cardiac APD data. We make no generalized claims about the
relative merits of these methods. However, we anticipate that
these ﬁndings will inform the analysis of future response-to-
challenge experiments. In addition, we have not attempted
to demonstrate the asymptotic validity of the bootstrap pro-
cedures considered herein. While others continue to estab-
lish the validity of various bootstrap estimators in nonlinear
regression (Hu and Kalbﬂeisch, 2000; Gonc¸alves and White,
2004, 2005; Chatterjee and Bose, 2005), we show that a nu-
merical strategy can be successful in evaluating a bootstrap
procedure in a narrow context.
Design, implementation, and analysis of response-to-
challenge experiments is a developing, multidisciplinary en-
deavor to study complex biology. This manuscript considers
several key statistical issues that are likely to emerge in the
analysis of data resulting from response-to-challenge experi-
ments. We conclude with a discussion of the outstanding sta-
tistical problems, including the promising opportunities asso-
ciated with optimal experimental design.
2. Experimental Data
The experiments we consider were conducted on 14 isolated
live rabbit hearts. Seven hearts were perfused with normal me-
dia and seven with amino acid enriched media (i.e., with the
amino acids glutamine and glutamate). The experiment was
designed to assess the cardioprotective eﬀect of amino acid
enrichment under anoxic challenge. The durations of cardiac




















Figure 1. Raw action potential durations for 14 isolated
rabbit hearts. Each heart was observed for up to 72minutes.
The vertical gray bars represent the periods of anoxia chal-
lenge.
action potentials (APD) were observed at 1 or 2minute inter-
vals for up to 72minutes. All hearts were observed at baseline
for up to 20minutes. In two subsequent time periods, hearts
were challenged with anoxia by withholding oxygen from the
perfusion media. The two challenges lasted for 6minutes each,
and were separated by 20minutes of recovery. Hence, the time
series is characterized by a sequence of ﬁve adjacent time pe-
riods: baseline, ﬁrst anoxia, ﬁrst recovery, second anoxia, and
second recovery. Figure 1 illustrates the time course of raw
APD measurements on each heart.
3. Statistical Modeling Approach
We considered a nonlinear regression model of the form
yijk = αj + η(tk, θi) + ijk (1)
where yijk is the measured APD on heart j ∈ {1, 2, . . . , 14} at
time tk ∈ {−20,−19, . . . , 50}, under perfusion with media type
i ∈ {E,N}. The intercept αj represents the baseline APD for
heart j. This varies among hearts due to innate diﬀerences
and instrument recalibration. The function η(tk, θi) gives the
average change in APD from baseline until time tk, given a
ﬁxed parameter θi. Finally, ijk is a random error with mean
zero. The intercepts were considered ﬁxed rather than ran-
dom to avoid the multiplicity of deﬁnitions for “residuals” in
models that have random eﬀects (Nobre and Singer, 2007),
and more importantly, because the correlations among errors
were modeled directly. The disadvantages of this approach
are that (1) each αj must be estimated and (2) no model is
available for the purpose of simulating new α values. The for-
mer is not serious because there were many measurements on
each heart. In the simulations described below, new α values
were drawn from the empirical distribution deﬁned by the
estimated values {αˆ1, αˆ2, . . . , αˆ14}.
Controlled anoxia challenges demonstrated a strong eﬀect
on cardiac APD. Within each anoxia period, the time course
of APD was characterized by a small initial upswing, followed
by a sharp decline. The recovery periods were characterized
by a sharp initial upswing, followed by a period of stability.
APD also exhibited a slow decay in time starting at the
ﬁrst exposure to anoxia and persisting throughout the
experiment. This sharp, irregular response led us to develop
100
Mechanistic Analysis of Response-to-Challenge Experiments 743
a piecewise diﬀerential equation model for the change in
mean APD over time. We had brieﬂy considered a restricted
cubic splines (Harrell, 2006) model, but found that the cubic
splines enforced a high degree of smoothness (Wegman and
Wright, 1983) that failed to capture the sharp transitions
between the baseline, anoxia, and recovery periods. More
importantly, the splines model is not mechanistic, in the sense
that predictions about APD under alternative experimental
designs (i.e., diﬀerent types of challenge) are not possible.
We rationalized that the heart would initially compensate
for mildly anoxic conditions by contracting longer and with
more force, resulting in lengthened cardiac action potentials.
However, prolonged anoxia restricts oxidative metabolism and
deprives cardiac tissue of the energy needed for contraction,
resulting in shortened action potentials. On reintroduction
of oxygenated media, oxidative metabolism is restored and
APD quickly recovers to near pre-challenge levels. The heart
is weakened as a result of anoxia, causing a slow decay in
APD over time. We hypothesized that perfusion with amino
acid enriched media would decelerate this anoxia-initiated de-
cay in APD. These mechanisms were modeled using a system
of piecewise ordinary diﬀerential equations that relate action
potential duration (D), the proportion of oxygen available for
oxidative metabolism (O), and a third proportion (E) that
represents the unspeciﬁc cellular and metabolic resources that
are necessary to sustain a cardiac action potential.
Using X′ = dX
dt
to denote the derivative of X with respect
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where ta0 and ta1 are the ﬁrst and second anoxia start times,
respectively, and tr0 and tr1 are the corresponding anoxia stop
times. The expressions for O′ and E′ are each given in ﬁve
pieces, corresponding to the ﬁve distinct experimental phases.
Each anoxia is associated with an “oﬀset;” the period of time
between the start of anoxia, and the point where metabolic
resources (i.e., the quantity modeled by E) begin to deplete.
The lengths of the “oﬀset” periods are denoted toﬀ0 and toﬀ1
for the transitions from baseline to the ﬁrst anoxia, and from
the ﬁrst recovery to the second anoxia, respectively. The times
ta0 , ta1 , tr0 , and tr1 are ﬁxed aspects of the experimental de-
sign. The unknown times toﬀ0 and toﬀ1 are treated as model
parameters.
The parameter k1 represents the rate of slow decay in APD.
All remaining parameters aﬀect the behavior of APD in re-
sponse to anoxia. The values of l0 and m0 represent the rates of
oxygen and bioenergetic resource depletion during the anoxia
periods, respectively, and l1 and m1 are the corresponding
rates of replenishment during the recovery periods. All un-
known model parameters were estimated simultaneously us-
ing one of the methods described below, under “Estimation
and Inference Strategies.”
While D measures APD in milliseconds, O and E are unit-
less proportions, where 1 represents full availability and 0 rep-
resents complete exhaustion. The initial (baseline) values for
D, O, and E were ﬁxed to 0, 1, and 1, respectively. This system
of equations (3) yields analytical solutions for D(t), O(t), and
E(t) (see Web Appendix and Web Figure 4). For the analysis
at hand, only the solution for D(t) is used.
The solution for D(t) given θi = {k0, k1i, l0, l1,m0i, m1i, toﬀ0 ,
toﬀ1} is denoted Di(tk), and substituted for η(tk, θi) in Equation
(1). Because the degree of anoxia was controlled, and since
amino acid enrichment was thought to aﬀect the metabolic
process, only the parameters k1i, m0i, and m1i were allowed
to vary by perfusion media type (i.e., by index i). Hence, this
mechanistic model permits comparisons of normal and amino
acid enriched media treatments in terms of their eﬀect on
(1) the rates of depletion and replenishment of bioenergetic
resources (m0i, and m1i) during and after an anoxic challenge,
and (2) the severity of cardiac tissue weakening caused by the
initial anoxic stress (k1i).
4. Estimation and Inference Strategies
Accurate assessment of variability is important for inferential
purposes, but also for our secondary objective: to predict the
variability in cardiac responses to alternative experimental
challenges (e.g., more frequent challenges, or for longer dura-
tions). The covariance structure in the cardiac APD data is
complex. In order to characterize the variability in these data,
three diﬀerent methods for estimation and inference were con-
sidered.
In the following discussion, the terms “parametric” and
“nonparametric” refer to the methods used to evaluate the
sampling distribution of estimators. A method was consid-
ered parametric if the errors (i.e., ijk, for all i, j, and k) were
modeled as having arisen from a parametric probability distri-
bution, and variability about sample estimators was evaluated
under this assumption. Methods that fail to meet this cri-
terion were considered nonparametric. The terms “paramet-
ric” and “nonparametric” are not used in regard to the mean
model (E[yijk] = αj + η(tk, θi)), which is clearly parameterized.
The ﬁrst method is nonparametric. The model parameters
θi were estimated using the method of OLS. This method
was selected initially to help characterize the structure of
residual covariability in these data without specifying a
parametric error distribution. The adjusted (BCa) percentile
method (Efron, 1987; Davison and Hinkley, 1997) was
used to construct 95% conﬁdence intervals for each model
parameter, and a pointwise 95% conﬁdence band for the
diﬀerence in mean APD (DE(t) − DN(t)) associated with
amino acid enriched media versus normal media. A pointwise
(versus simultaneous) conﬁdence band was used in order to
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Figure 2. Ordinary least squares model ﬁt. The top panel
shows raw APD measurements (dotted lines) adjusted ver-
tically by subtracting the corresponding αˆj − α¯. Estimated
mean APD curves (solid lines) are overlaid. The lower panel
shows the estimated diﬀerence in mean APD for enriched ver-
sus normal media groups, with pointwise bootstrap 95% con-
ﬁdence band. In either panel, vertical gray bars delineate the
periods of anoxia challenge.
assess the diﬀerence in mean APD at the ﬁnal measurement
(52minutes). Hence, the reader should be cautioned against
drawing simultaneous inferences about the diﬀerence in mean
APD.
In order to preserve the complex covariance structure
among resamples, the time series of measurements on indi-
vidual hearts were considered clustered. Hence, whole clusters
were resampled with replacement. This method corresponds
to the cluster bootstrap of Field and Welsh (2007), a simpliﬁca-
tion of the multi-stage bootstrap for hierarchically structured
data (Davison and Hinkley, 1997). Seven clusters were resam-
pled from each of the normal and amino acid enriched media
groups. Recently, Crainiceanu et al. (2012) advocate for an
extension of this approach in a related application.
Ten thousand resamples were used for all bootstrap pro-
cedures. The bootstrap size was selected to ensure that the
2.5% and 97.5% bootstrap percentiles had coeﬃcient of vari-
ation (CV) < 0.01 for each estimator. The method of Maritz
and Jarrett (1978) and Efron (1979) was used to estimate the
variance of bootstrap percentiles.
It is well known that the bootstrap distributions for certain
types of estimators do not have the expected limiting behav-
ior (e.g., see Example 2.15, Davison and Hinkley, 1997). We
have not examined the asymptotic properties of the bootstrap
methods used herein. However, empirical studies have shown
the bootstrap to be reasonable for similar types of inferences
(Hinkley and Schechtman, 1987; Duggins, 2010).
Figure 2 illustrates the OLS-ﬁtted data, the estimated dif-
ference in mean APD, and the bootstrap-constructed 95%
conﬁdence band. Web Figure 5 illustrates the raw APD means































Figure 3. Residual analysis of the OLS model ﬁt. Upper
panel: estimated residual autocorrelation among time series
measurements, in lags up to 52minutes. Lower panel: esti-
mated residual variance at each time where measurements
were collected. The zero-lag time in the upper panel was
aligned with time zero in the lower panel to illustrate the eﬀect
of repeat anoxia challenge on the estimated autocorrelation.
However, note that autocorrelation estimates are increasingly
uncertain for higher lag times. The autocorrelation for lags
near 26minutes are artifacts of the experimental design (i.e.,
repeat anoxia). No signiﬁcant autocorrelation was observed
among the MLE standardized residuals (see Web Figure 2).
plotted against OLS-ﬁtted means, with good agreement. Web
Table 1 gives estimates and 95% conﬁdence intervals for each
model parameter. In particular, the rate of slow APD decay
(k1N vs. k1E) for the amino acid enriched media group was im-
proved by 1.2E−2 msmin−2 (95% CI: 2.6E−3, 2.2E−2), relative
to the normal media group. The rates of depletion and replen-
ishment of bioenergetic resources during anoxia and recovery
periods (m0N , m1N , m0E, m1E) were not signiﬁcantly diﬀerent
for the enriched versus normal media groups. However, bioen-
ergetic resources began to deplete 55 seconds (toﬀ0 − toﬀ1 ; 95%
CI: 39, 72) earlier following the second onset of anoxia (toﬀ1 ;
48 s, 95% CI: 31, 84) than at the ﬁrst (toﬀ0 ; 102 s, 95% CI: 90,
138). Although parameter estimates were slightly diﬀerent un-
der the two subsequent statistical strategies, the ﬁndings were
qualitatively consistent.
Analysis of residuals from the OLS-ﬁtted model revealed si-
gniﬁcant residual autocorrelation in APD measurements, and
increasing residual variance within the anoxia challenge per-
iods (heteroscedasticity). Figure 3 illustrates these ﬁndings.
The second estimation and inference strategy is fully para-
metric. Using the evidence illustrated by Figure 3, ijk was
modeled as having arisen from the normal distribution with
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cor(ijk, ijk′) = ρ|tk−tk′ |,
(3)
where all other correlations are zero, and ta is the time anoxia
was initiated (i.e., (tk − ta) measures the duration of anoxia).
This autoregressive construction approximates the types of
heteroscedasticity and autocorrelation observed in the cardiac
APD data. Speciﬁcally, the variance in APD measurement is
constant for baseline and recovery, but grows exponentially
within the anoxia periods. Hence, this parameterizes the no-
tion that perturbed biological systems behave more variably
(or measured with less precision) than systems at rest.
Given this distributional information, a MLE was con-
structed for θi, σ
2, ψ, and ρ. Variability about the MLE was
assessed using its asymptotic (i.e., normal) distribution, where
the covariance was estimated by the inverse observed Fisher
information, evaluated at the MLE. Monte-Carlo integration
was used to construct a pointwise 95% conﬁdence band for
the diﬀerence in mean APD.
He and Severini (2010) demonstrated that the maximum
likelihood estimator for parametric models with multiple un-
known change-points is consistent, and has a multivariate nor-
mal limiting distribution with covariance matrix identical to
the inverse Fisher information. Their result is valid under mild
regularity conditions.
Web Figure 1 illustrates the MLE-ﬁtted data, the estimated
diﬀerence in mean APD, and the pointwise asymptotic 95%
conﬁdence band. Web Figure 2 shows the estimated auto-
correlation and variance for the MLE standardized residuals.
Because no signiﬁcant autocorrelation was found among the
standardized residuals, the parametric correlation structure
given by expression (3) was considered suﬃcient. Web Ta-
ble 1 gives estimates and 95% conﬁdence intervals for each
parameter in θi, σ
2, ψ, and ρ.
The third and ﬁnal approach utilizes a likelihood-based es-
timator, but characterizes its variability nonparametrically:
the MLE was used, but variability about the MLE was as-
sessed using the nonparametric bootstrap, as before. The cor-
responding estimates and 95% conﬁdence intervals are given
in Web Table 1. Web Figure 3 illustrates the MLE-ﬁtted data
and estimated diﬀerence in mean APD as before, and the
pointwise bootstrap 95% conﬁdence band.
5. Simulation and Results
Because the processes that generate these experimental data
are unknown, it is impossible to assess the utility of com-
peting statistical methods under the “true” data-generating
mechanism. However, if a parametric process is assumed (as
is often done, for analytical and practical reasons), then our
assessment may artiﬁcially favor a parametric strategy, and
vice versa when empirical (nonparametric) or semiparametric
processes are assumed. We refer to this as “simulation bias.”
Indeed, nonparametric methods are often less eﬃcient than
parametric methods when the underlying data arise from the
corresponding parametric process (for a speciﬁc example, see



































Figure 4. Estimated pointwise power and coverage for each
of three strategies. The upper panel displays the pointwise
95% conﬁdence bands for each method using the original car-
diac APD data. The middle panel illustrates the estimated
power associated with tests of the pointwise null hypothesis
H0 : DE(t) − DN(t) = 0. The gray horizontal lines represent
typical values of interest (i.e., 0.80 and 0.05). The lower panel
shows the estimated coverage for pointwise 95% conﬁdence
bands. The gray horizontal line represents the nominal cover-
age (0.95).
To counter this potential bias, we constructed a data gen-
erating mechanism from an equal mixture (i.e., with mixing
probability 0.5) of parametric and nonparametric processes.
The former was taken as the MLE-ﬁtted model in the sec-
tion above. The nonparametric process was identical to the
empirical distribution over clustered APD measurements, ad-
justed so that the mean APD at each time point matched that
of the parametric process. Five hundred new data sets were
simulated by this mechanism. The size of treatment groups,
and frequency and spacing of measurements in time were sim-
ulated to match the original cardiac APD experiment.
For each of the estimation and inference alternatives de-
scribed in the preceding section, the pointwise coverage and
power associated with pointwise null hypotheses were evalu-
ated. For each time point, the pointwise coverage was com-
puted as the frequency of 95% conﬁdence intervals that cov-
ered the “true,” simulated diﬀerence in mean APD. The
pointwise null hypothesis H0(t) : DE(t) − DN(t) = 0 was re-
jected when the corresponding 95% conﬁdence interval failed
to include zero. Note that this testing strategy does not ensure
a ﬁxed type I error rate. Statistical power was approximated
by the rejection frequency in simulated experiments.
Figure 4 illustrates the pointwise coverage and power for
1500 simulated experiments. In particular, the asymptotic
MLE method is anticonservative about the mean APD
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estimate, especially within the anoxia periods. As a
consequence, the coverage was lesser in these regions, and
generally worse than that of the bootstrap methods. However,
all methods exhibited less coverage than the nominal level.
Statistical power was generally greater for the asymptotic
MLE method versus the bootstrap MLE method. In the most
powerful regions (i.e., late in the recovery periods), the diﬀer-
ence in estimated power was near 0.10.
Because the simulated diﬀerence in mean APD was nonzero
at every time point beyond the baseline period, the pointwise
type I error rate was not estimated. However, the simulated
diﬀerence was near zero shortly after initiating the ﬁrst anoxia
challenge. Hence, the estimated power is a rough gauge of
the type I error rate in this region. Figure 4 indicates that
the approximate type I error rate for the asymptotic MLE
method was near 0.20. Rates for the bootstrap methods were
near 0.10.
It is of particular interest that the bootstrap OLS method
did not have signiﬁcantly better or worse estimated coverage
than the bootstrap MLE method, even though the MLE ex-
plicitly accounts for the complex covariation observed in these
data, and is asymptotically more eﬃcient (i.e., under certain
regularity conditions that were not veriﬁed in the present con-
text; Casella and Berger, 2001, p. 472).
6. Discussion
There are signiﬁcant costs and beneﬁts associated with para-
metric methods that cannot be quantiﬁed in simple statistical
measures (e.g., coverage and the rates of type I and II errors).
For example, parametric error strategies often require greater
human eﬀort and other resources (e.g., model building, di-
agnostics, additional computer optimization, etc.). When the
error structure has little inherent scientiﬁc value, the addi-
tional eﬀort may not be worthwhile. Indeed, our analysis of
the cardiac APD data revealed little beneﬁt, in terms of cov-
erage and power, associated with the bootstrap MLE versus
bootstrap OLS methods.
In the current context, there is scientiﬁc value in charac-
terizing the changes in variability of APD as a consequence
of anoxia challenge. In particular, this is important in the de-
sign of future response-to-challenge experiments, where the
number, duration, and spacing of challenges are design pa-
rameters.
To illustrate, consider a hypothetical experiment that aims
to evaluate whether average APD continues to decline under
anoxic conditions, or stabilizes at some time after the onset
of anoxia. Let the design be identical to the cardiac APD ex-
periment considered above, except that each anoxia challenge
is prolonged by some amount tpro. An alternative mechanistic
model that accommodates the stabilization behavior is then
proposed in order to evaluate the competing hypotheses. Both
models may be ﬁtted to preliminary data, and used to predict
the behavior of APD under the hypothetical experiment.
The value of tpro may then be selected to render the largest
discrepancy in predictions between the two competing mod-
els (e.g., using the KL-optimality criterion of Lo´pez-Fidalgo,
Tomassi, and Trandaﬁr (2007)). Because the variance in APD
increases exponentially within the anoxia periods, a model
and design criterion that account for this are necessary to
fully evaluate the hypothetical experiment. In other words,
prolonged anoxia is expected to result in continued APD de-
cline, but the accompanying increase in variability may im-
pose a constraint on the length of anoxia challenges. Indeed,
suﬃciently long exposure to anoxia results in ﬁbrillation (and
ultimately cardiac arrest), a physiological state where APD
measurements are variable in the extreme.
Other types of hypotheses about the cardiac APD mecha-
nism may beneﬁt from the application of more conventional
optimal design methods (i.e., those that aim to maximize a
function of the Fisher information about one or more model
parameters; see Fedorov (2010) for a recent review). The com-
bination of mechanistic mean modeling and parametric error
modeling makes this possible. Because the challenge charac-
teristics are the crux of a response-to-challenge experiment,
strategies for optimizing its design promise signiﬁcant and
powerful new insights in this ﬁeld.
Supplementary Material
The Web Appendix, Figures, and Table referenced in Sections
3 and 4 are available with this paper at the Biometrics website
on Wiley Online Library.
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The differential equations listed in manuscript equation (2) yield analytical solutions for
D(t), E(t), and O(t). The starting values (i.e., for times t ≤ ta0) for D(t), O(t), and E(t)
are 0, 1, and 1, respectively. Web Figure 4 illustrates the solution for D(t), the anoxia start
times (ta0 and ta1), anoxia end times (tr0 and tr1), and the offset lengths (toff0 and toff1). The
solutions are as follows:
D(t) =
{
0 t ≤ ta0
k0(E(t)−O(t))− k12 (t− ta0)2 ta0 < t
O(t) =

1 t ≤ ta0
O(ta0)e
−l0(t−ta0 ) ta0 < t ≤ tr0
1− (1−O(tr0))e−l1(t−tr0 ) tr0 < t ≤ ta1
O(ta1)e
−l0(t−ta1 ) ta1 < t ≤ tr1
1− (1−O(tr1))e−l1(t−tr1 ) tr1 < t
E(t) =

1 t ≤ ta0 + toff0
O(ta0 + toff0)e
−m0(t−ta0−toff0 ) ta0 + toff0 < t ≤ tr0
1− (1− E(tr0))e−m1(t−tr0 ) tr0 < t ≤ ta1 + toff1
O(ta1 + toff1)e
−m0(t−ta1−toff1 ) ta1 + toff1 < t ≤ tr1





Web Table 1: Estimates and 95% confidence intervals for each model parameter, using each
statistical inference mechanism (Bootstrap OLS, Bootstrap MLE, and Asymptotic MLE).
For the parameters that varied by perfusion media type (k1, m0, m1), and the offset lengths,
an estimate and confidence interval are given for their difference. Estimates were computed
using APD measured in milliseconds, observation time measured in minutes, and oxygen
and metabolic resources measured in arbitrary units. Hence, the unit of measurement for
each estimate is a derivative of milliseconds, minutes, units of oxygen, or units of metabolic
resource. For example, k1 is measured in milliseconds per minute per minute. However, these
estimates were converted to SI units (e.g., ms · s−2) for presentation within the manuscript
body.
Parameter Bootstrap OLS Bootstrap MLE Asymptotic MLE
k0 1.8E+2 (1.0E+2, 3.0E+2) 2.4E+2 (1.3E+2, 5.8E+2) 2.3E+2 (7.8E+1, 3.8E+2)
k1N 1.7E−2 (1.0E−2, 2.7E−2) 1.8E−2 (1.0E−2, 2.8E−2) 1.8E−2 (1.3E−2, 2.3E−2)
k1E 5.8E−3 (5.3E−4, 1.2E−2) 7.1E−3 (2.0E−3, 1.3E−2) 7.2E−3 (2.1E−3, 1.2E−2)
k1N − k1E 1.2E−2 (2.6E−3, 2.2E−2) 1.1E−2 (1.3E−3, 2.2E−2) 1.1E−2 (3.9E−3, 1.8E−2)
l0 4.8E−2 (2.9E−2, 6.7E−2) 3.6E−2 (1.8E−2, 5.7E−2) 3.5E−2 (1.1E−2, 5.9E−2)
l1 1.6E+0 (1.0E+0, 2.7E+0) 1.8E+0 (9.9E−1, 3.8E+0) 1.5E+0 (9.5E−1, 2.0E+0)
m0N 1.7E−1 (7.5E−2, 3.0E−1) 1.2E−1 (4.5E−2, 2.7E−1) 1.1E−1 (2.6E−2, 1.9E−1)
m0E 1.5E−1 (7.6E−2, 2.4E−1) 1.1E−1 (3.0E−2, 1.8E−1) 1.0E−1 (2.6E−2, 1.7E−1)
m0N −m0E 1.9E−2 (−6.7E−2, 1.5E−1) 1.1E−2 (−5.2E−2, 1.6E−1) 7.4E−3 (−1.0E−2, 2.5E−2)
m1N 5.8E−1 (3.9E−1, 7.4E−1) 5.8E−1 (4.1E−1, 7.4E−1) 5.9E−1 (4.9E−1, 7.0E−1)
m1E 6.5E−1 (5.6E−1, 8.0E−1) 6.2E−1 (5.1E−1, 7.6E−1) 6.3E−1 (5.2E−1, 7.4E−1)
m1E −m1N 7.6E−2 (−2.9E−2, 2.2E−1) 4.2E−2 (−6.4E−2, 1.8E−1) 3.5E−2 (−6.2E−2, 1.3E−1)
toff0 1.7E+0 (1.5E+0, 2.3E+0) 1.7E+0 (1.4E+0, 2.0E+0) 1.6E+0 (1.4E+0, 1.8E+0)
toff1 8.0E−1 (5.2E−1, 1.4E+0) 7.8E−1 (3.0E−1, 1.4E+0) 7.4E−1 (5.5E−1, 9.2E−1)
toff0 − toff1 9.2E−1 (6.5E−1, 1.2E+0) 8.8E−1 (3.3E−1, 1.5E+0) 9.1E−1 (6.9E−1, 1.1E+0)
ρ — 8.1E−1 (7.2E−1, 8.8E−1) 8.1E−1 (7.7E−1, 8.6E−1)
ψ — 1.5E−1 (9.6E−2, 1.9E−1) 1.5E−1 (1.2E−1, 1.7E−1)



































Web Figure 1: Maximum likelihood model fit. The top panel shows raw APD measurements
(dotted lines) adjusted vertically by subtracting the corresponding αˆj. Estimated mean APD
curves (solid lines) are overlaid. The lower panel shows the estimated difference in mean APD
curves for enriched versus normal media groups, with pointwise asymptotic 95% confidence
band. In either panel, vertical gray bars delineate the periods of anoxia challenge.
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Web Figure 2: Standardized residual analysis of the MLE model fit. Upper panel: estimated
residual autocorrelation among time series measurements, in lags up to 52 minutes. Lower
panel: estimated residual variance at each time where measurements were collected. The
zero-lag time in the upper panel was aligned with time zero in the lower panel to illustrate
the effect of repeat anoxia challenge on the estimated autocorrelation. However, note that



































Web Figure 3: Maximum likelihood model fit. The top panel shows raw APD measurements
(dotted lines) adjusted vertically by subtracting the corresponding αˆj. Estimated mean APD
curves (solid lines) are overlaid. The lower panel shows the estimated difference in mean APD
curves for enriched versus normal media groups, with pointwise bootstrap 95% confidence











Time Relative to First Anoxia (min)
D
(t)
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Web Figure 4: Diagram of the solution for D(t). Gray regions represent the two periods of
anoxia challenge.





























































Web Figure 5: Raw APD means plotted against OLS fitted means. Raw APD means are
adjusted adjusted vertically by subtracting the corresponding αˆj from each raw APD mea-
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